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Abstract: Homologous recombination (HR) is a mostly accurate DNA repair pathway, which takes place
in the S-phase of the cell cycle. It repairs DNA double-strand breaks (DSBs), DNA single-strand breaks
and contributes to the repair of interstrand DNA crosslinks. While the mechanism of a two-ended DSB is
relatively well understood, how recombination restores DNA integrity upon replisome stalling or collapse,
remains poorly understood. In yeast, Mms22 was found to promote homologous recombination specifi-
cally upon DNA replication fork stalling. In human cells, the human homologue MMS22L (Mms22-like)
forms a complex with TONSL (Tonsoku-like). MMS22L-TONSL complex localizes at sites of damaged
DNA upon laser microirradiation. Depletion of MMS22L or TONSL caused hypersensitivity to a variety
of DNA-damaging drugs that interfere with DNA replication. Furthermore, depletion of MMS22L or
TONSL resulted in persistent RPA foci and decreased formation of RAD51 foci. These data suggested
that MMS22L-TONSL complex might play a role in the initiation of HR- dependent repair specifically
downstream of DNA end resection prior to RAD51 loading. The aim of this project was to perform
biochemical analyses to investigate the potential role of MMS22L-TONSL in HR, in particular as a
recombination mediator. Recombination mediators, such as BRCA2 or RAD51 paralogs, help to load
RAD51 on RPA-coated ssDNA. RAD51 then performs search for homologous DNA duplex, which subse-
quently leads to HR repair. First, we purified MMS22L-TONSL complex from Sf9 insect cell expression
system. The complex purified as heterodimer. We then tested its ability to bind various DNA substrates.
We found that MMS22L-TONSL complex binds long stretches of DNA, suggesting that DNA might
be bound cooperatively. Furthermore, MMS22L-TONSL complex bound RPA-coated ssDNA. Next we
tested direct protein- protein interactions between MMS22L-TONSL or MMS22L and RAD51. Strik-
ingly, RAD51 binds both MMS22L-TONSL and MMS22L, suggesting that MMS22L is the interacting
subunit. MMS22L-TONSL also facilitates RAD51-dependent DNA strand exchange activity in an ATP-
dependent manner by lowering RAD51’s binding affinity to dsDNA. As a result, this facilitates RAD51
filament formation on single-stranded DNA when dsDNA is present. Our data collectively support a
notion that MMS22L-TONSL acts in homologous recombination as a recombination mediator, similarly
as BRCA2 and RAD51 paralogs such as RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3.
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ZUSAMMENFASSUNG	  
	  	   Die	   homologe	   Rekombination	   (HR)	   ist	   ein	   meist	   fehlerfreier	   DNS	  Reparaturmechanismus,	  welcher	  während	  der	  S-­‐Phase	  des	  Zellzyklus	  stattfindet.	  HR	  wird	  verwendet	  um	  DNS-­‐Doppelstrangbrüche	  (DSBs),	  DNS-­‐Einzelstrangbrüche	  und	  sogenannte	  DNA-­‐Vernetzungen	  zu	  reparieren.	  Der	  Mechanismus	   für	  die	  Reparatur	  von	  zwei-­‐endigen	  DSB	  ist	  relativ	  genau	  bekannt,	  während	  weniger	  darüber	  bekannt	  ist,	   wie	   die	   Rekombination	   die	   DNS-­‐Integrität	   nach	   Schäden,	   die	   durch	   die	  Verlangsamung	  und	  oder	  den	  Kollaps	  des	  Replisomes	  entstehen,	  aufrechterhält.	  Das	   Hefe-­‐Protein	  Mms22	   ist	   speziell	   für	   die	   	   homologe	   Rekombination	   nach	   dem	  Abriss	  der	  DNS-­‐Replikationsgabel	  verantwortlich.	  Die	  Homologe	  MMS22L	  (Mms22-­‐like)	  und	  TONSL	  (Tonsoku-­‐like)	  bilden	  einen	  Komplex	  in	  menschlichen	  Zellen.	  Nach	  Laser-­‐induzierten	   DNS-­‐Schäden	   lokalisiert	   der	   MMS22L-­‐TONSL	   Komplex	   an	  ebendiese.	  Zellen,	  welche	  kein	  MMS22L	  oder	  TONSL	  besitzen,	  sind	  hypersensitiv	  für	  DNS-­‐Schäden-­‐induzierende	  Stoffe	  welche	  mit	  der	  DNS	  Replikation	  interferieren.	  Des	  Weiteren	   zeigen	   Zellen,	   welche	   kein	   MMS22L	   oder	   TONSL	   exprimieren,	  langanhaltende	   RPA	   Foki	   und	   weniger	   RAD51	   Foki.	   Diese	   Erkenntnisse	   deuten	  darauf	   hin,	   dass	   der	   MMS22L-­‐TONSL	   Komplex	   wichtig	   für	   die	   Initiation	   der	   HR-­‐abhängigen	  Reparatur	  ist	  und	  eine	  Funktion	  nach	  der	  DNA-­‐Resektion	  und	  vor	  dem	  Laden	  von	  RAD51	  hat.	  	  	   Das	   Ziel	   dieses	   Projektes	   war	   es,	   die	   mögliche	   Funktion	   des	   MMS22L-­‐TONSL	  Komplex	  in	  der	  homologen	  Rekombination,	  vor	  allem	  als	  Rekombination-­‐Mediators	  mittels	   biochemischen	   Analysen	   zu	   untersuchen.	   Rekombination-­‐Mediatoren	   wie	  zum	   Beispiel	   BRCA2	   oder	   RAD51	   Paraloge	   spielen	   eine	   Rolle	   beim	   Laden	   von	  RAD51	  auf	  RPA-­‐bedeckte	  einzelsträngige	  DNS.	  	  RAD51	  sucht	  danach	  homologe	  DNS	  Abschnitte	  was	  im	  Weiteren	  zu	  HR	  Reparatur	  führt.	  	  Als	  erstes	  haben	  wir	  den	  MMS22L-­‐TONSL	  Komplex	  in	  Sf9	  Insektenzellen	  exprimiert.	  Der	   Komplex	   liegt	   als	   Heterodimer	   vor.	   	   Wir	   untersuchten	   die	   Fähigkeit	   des	  Komplexes	  an	  DNS-­‐Substrate	  zu	  binden	  und	  fanden,	  dass	  MMS22L-­‐TONSL	  an	  lange	  DNS	  Moleküle	  bindet.	  	  	   MMS22L-­‐TONSL	   bindet	   auch	   an	   einzelsträngige	   DNS	   welche	   schon	   von	   RPA	  gebunden	  ist.	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SUMMARY	  
	  	   Homologous	  recombination	  (HR)	  is	  a	  mostly	  accurate	  DNA	  repair	  pathway,	  which	  takes	   place	   in	   the	   S-­‐phase	   of	   the	   cell	   cycle.	   It	   repairs	   DNA	   double-­‐strand	   breaks	  (DSBs),	  DNA	  single-­‐strand	  breaks	  and	  contributes	  to	  the	  repair	  of	   interstrand	  DNA	  crosslinks.	  While	  the	  mechanism	  of	  a	   two-­‐ended	  DSB	  is	  relatively	  well	  understood,	  how	   recombination	   restores	   DNA	   integrity	   upon	   replisome	   stalling	   or	   collapse,	  remains	  poorly	  understood.	  	   In	   yeast,	   Mms22	  was	   found	   to	   promote	   homologous	   recombination	   specifically	  upon	  DNA	  replication	  fork	  stalling.	   In	  human	  cells,	   the	  human	  homologue	  MMS22L	  (Mms22-­‐like)	   forms	   a	   complex	   with	   TONSL	   (Tonsoku-­‐like).	   MMS22L-­‐TONSL	  complex	  localizes	  at	  sites	  of	  damaged	  DNA	  upon	  laser	  microirradiation.	  Depletion	  of	  MMS22L	  or	  TONSL	  caused	  hypersensitivity	  to	  a	  variety	  of	  DNA-­‐damaging	  drugs	  that	  interfere	   with	   DNA	   replication.	   Furthermore,	   depletion	   of	   MMS22L	   or	   TONSL	  resulted	   in	  persistent	  RPA	   foci	  and	  decreased	   formation	  of	  RAD51	   foci.	  These	  data	  suggested	   that	  MMS22L-­‐TONSL	   complex	  might	   play	   a	   role	   in	   the	   initiation	   of	   HR-­‐dependent	   repair	   specifically	   downstream	   of	   DNA	   end	   resection	   prior	   to	   RAD51	  loading.	  	   The	   aim	   of	   this	   project	  was	   to	   perform	   biochemical	   analyses	   to	   investigate	   the	  potential	  role	  of	  MMS22L-­‐TONSL	   in	  HR,	   in	  particular	  as	  a	  recombination	  mediator.	  Recombination	  mediators,	  such	  as	  BRCA2	  or	  RAD51	  paralogs,	  help	  to	  load	  RAD51	  on	  RPA-­‐coated	  ssDNA.	  RAD51	  then	  performs	  search	  for	  homologous	  DNA	  duplex,	  which	  subsequently	  leads	  to	  HR	  repair.	  	   First,	   we	   purified	   MMS22L-­‐TONSL	   complex	   from	   Sf9	   insect	   cell	   expression	  system.	   The	   complex	   purified	   as	   heterodimer.	   We	   then	   tested	   its	   ability	   to	   bind	  various	   DNA	   substrates.	   We	   found	   that	   MMS22L-­‐TONSL	   complex	   binds	   long	  stretches	  of	  DNA,	  suggesting	  that	  DNA	  might	  be	  bound	  cooperatively.	  Furthermore,	  MMS22L-­‐TONSL	  complex	  bound	  RPA-­‐coated	  ssDNA.	  Next	  we	  tested	  direct	  protein-­‐protein	   interactions	   between	   MMS22L-­‐TONSL	   or	   MMS22L	   and	   RAD51.	   Strikingly,	  RAD51	   binds	   both	   MMS22L-­‐TONSL	   and	   MMS22L,	   suggesting	   that	   MMS22L	   is	   the	  interacting	   subunit.	  MMS22L-­‐TONSL	   also	   facilitates	  RAD51-­‐dependent	  DNA	   strand	  exchange	  activity	  in	  an	  ATP-­‐dependent	  manner	  by	  lowering	  RAD51's	  binding	  affinity	  to	  dsDNA.	  As	  a	  result,	   this	   facilitates	  RAD51	   filament	   formation	  on	  single-­‐stranded	  DNA	  when	  dsDNA	   is	  present.	  Our	  data	  collectively	  support	  a	  notion	   that	  MMS22L-­‐
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TONSL	  acts	  in	  homologous	  recombination	  as	  a	  recombination	  mediator,	  similarly	  as	  BRCA2	  and	  RAD51	  paralogs	  such	  as	  RAD51B,	  RAD51C,	  RAD51D,	  XRCC2,	  and	  XRCC3.	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1 INTRODUCTION	  	  
1.1 HOMOLOGOUS	  RECOMBINATION	  	  	   Homologous	  recombination	  (HR)	  is	  a	  high	  fidelity	  repair	  pathway	  that	  recognizes	  and	  repairs	  DNA	  lesions	   including	  double-­‐strand	  DNA	  breaks	  (DSBs),	  single-­‐strand	  DNA	  (ssDNA)	  breaks,	  and	  contributes	  to	  the	  repair	  of	  interstrand	  DNA	  crosslinks	  in	  S	   and	   G2	   phases	   of	   the	   cell	   cycle.1,2	   In	   contrast,	   the	   non-­‐homologous	   end-­‐joining	  (NHEJ)	   pathway	   is	   responsible	   for	   repairing	   DSBs	   throughout	   the	   cell	   cycle	   by	  ligating	   the	   processed	   DNA	   ends.	   HR	   copies	   the	   missing	   DNA	   information	   from	  homologous	  DNA	   regions,	   such	  as	   sister	   chromatids,	   resulting	   in	   a	  highly	   accurate	  repair	  mechanism.2	  	   Homologous	  recombination	  is	  initiated	  by	  5'	  DNA	  end	  resection;	  this	  step	  requires	  three	   nucleases,	   including	   MRE11-­‐RAD50-­‐NBS1	   (MRN	   complex),	   Exonuclease	   I	  (Exo1),	   and	  DNA2	   in	   conjunction	  with	  helicases	  Bloom	  syndrome	  protein	   (BLM)	  or	  Werner	   syndrome	  helicase.3,4	   First,	  MRN	  complex	  binds	   to	   the	  DSB	  and	   serves	  as	   a	  sensor	  of	  a	  DSB	  and	  signals	  it	  to	  the	  downstream	  factors	  as	  well.	  Then,	  the	  DSBs	  are	  processed	  by	  MRN	  together	  with	  CtIP	  5,6	  creating	  a	  3'	  ssDNA	  overhang	  to	  be	  further	  processed	  by	  either	  BLM-­‐DNA2	  or	  WRN-­‐DNA2	  together	  or	  with	  Exo1	  and	  resulting	  in	  a	   long-­‐range	  DNA	  end	   resection.3,6	   Those	   extensively	   processed	  3'-­‐ends	   are	   rapidly	  covered	   by	   the	   replication	   protein	   A	   (RPA)	   to	   prevent	   formation	   of	   secondary	  structures	   and	   protect	   the	   naked	   DNA.7	   RPA	   is	   then	   replaced	   with	   recombinase	  RAD51.	   Since	   RPA	   has	   an	   inhibitory	   effect	   on	   RAD51	   binding	   to	   ssDNA,	   this	   step	  requires	  recombination	  mediators,	  which	  are	   the	   focus	  of	   this	   thesis.	  RAD51-­‐coated	  ssDNA	   filament	   (presynaptic	   filament)	   is	   later	   stabilized	   by	   RAD54.	   RAD51	   then	  performs	   strand	   invasion	   into	   the	   sister	   chromatid	   and	   searches	   for	   homologous	  region	   in	   a	   rather	   random	  manner	   by	   testing	   various	   segments	   of	   the	   donor	   DNA	  duplex.	  Once	  the	  3'-­‐end	  ssDNA	  overhang	  is	  paired	  to	  an	  appropriate	  region,	  it	  forms	  a	  displacement	   loop	  (D-­‐loop).	  RAD54	  then	  facilitates	  RAD51	  dissociation	  from	  ssDNA,	  allowing	   DNA	   polymerases	   to	   fill	   up	   the	   gap.	   There	   are	   two	   sub	   pathways	   in	   DSB	  repair,	  synthesis-­‐dependent	  strand	  annealing	  (SDSA)	  and	  double-­‐strand	  break	  repair	  pathway	   (DSBR).	   They	   both	   share	   the	   initial	   steps	   of	   HR	   but	   differ	   in	   downstream	  steps	  of	  RAD51	  filament	  formation.	  In	  SDSA,	  once	  the	  gap	  is	  synthetized,	  the	  invading	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strand	  is	  re-­‐annealed	  back	  to	  the	  original	  DNA	  strand	  before	  the	  breakage.	  This	  sub	  pathway	  produces	  only	  non-­‐crossover	  products.	   In	  DSBR,	  on	  the	  other	  hand,	  Rad52	  captures	   the	   second	  end	  of	   the	  broken	  DNA	  and	   anneals	   it	   to	   the	  D-­‐loop	   structure,	  forming	   a	   double	  Holliday	   junction	   (dHJ).	   Once	   the	   gaps	   are	   filled,	   dHJ	   structure	   is	  later	  resolved	  into	  crossover	  (CO)	  or	  noncrossover	  (NCO)	  products	  (Figure	  1).1,2,8,9,4	  	   There	   are	   three	   pathways,	   which	   evolved	   to	   process	   dHJs.	   First,	   dissolution	  pathway	   involves	  BLM-­‐TOPOIIIα-­‐RMI1-­‐RMI2	  (BTR)	  complex,	  which	   is	  employed	   in	  the	  S	  phase	  of	   the	  cycle	  and	  generates	  exclusively	  NCO	  products	   to	  prevent	   loss	  of	  heterozygosity	   in	  mitotic	  cells.	  The	  second,	  resolution	  pathway,	   is	  catalyzed	  by	   the	  SLX1-­‐SLX4-­‐MUS81-­‐EME1	  (SLX-­‐MUS)	  complex	  and	  results	  in	  the	  mixture	  of	  both	  CO	  and	   NCO	   products.	   The	   third	   involves	   GEN1,	   an	   enzyme	   functioning	   in	   resolution	  pathway	   to	   process	   dHJs	   in	   case	   of	   missing	   function	   of	   BTR	   and/or	   SLX-­‐MUS	  enzymes.10,11	  	   In	  meiotic	  cells,	  DSBs	  are	  introduced	  intentionally	  in	  order	  to	  generate	  crossover	  products	   subsequently	   resulting	   in	   genetic	   diversity.	   Such	   events	   require	   factors	  specific	   for	  meiotic	   recombination,	   such	   as	  Dmc1	   (disrupted	  meiosis	   cDNA	  1)	   and	  Hop2-­‐Mnd1	  complex,	  which	  will	  be	  further	  discussed	  below	  in	  the	  text.	  Dmc1	  is	  only	  expressed	  in	  meiosis	  and	  shares	  up	  to	  50%	  sequence	  similarity	  with	  Rad51;	  in	  fact,	  both	   Rad51	   and	   Dmc1	   are	   homologs	   of	   bacterial	   RecA,	   mentioned	   below.	   Both	  Rad51	  and	  Dmc1	  bind	  to	  3'	  resected	  ssDNA	  ends	  of	  the	  DSB	  and	  with	  help	  of	  Hop2-­‐Mnd1	  heterodimer	  generate	  the	  D-­‐loop,	  the	  first	  recombination	  intermediate.12-­‐14	  	   On	  the	  contrary	  to	  eukaryotes,	  in	  bacteria	  Escherichia	  coli	  (E.	  coli),	  the	  DNA	  breaks	  are	   mainly	   repaired	   by	   homologous	   recombination.	   Moreover,	   two	   overlapping	  pathways	   evolved,	   namely	   the	   RecBCD	   and	   RecF	   pathways.	   RecBCD	   is	   employed	  when	   dsDNA	   breaks	   occur,	   whereas	   the	   second	   pathway,	   RecF,	   primarily	   repairs	  single-­‐stranded	  DNA	  gaps	   that	   arise	  during	   replication	  process	  of	   a	  damaged	  DNA	  template.	  RecF	  can	  also	  repair	  dsDNA	  breaks	  as	  a	  compensatory	  pathway	  to	  RecBCD.	  15	   In	  the	  RecBCD	  pathway,	  once	  the	  DSB	  is	  detected,	  the	  RecBCD	  helicase/nuclease	  binds	  to	  the	  DSB	  and	  starts	  processing	  the	  ends.	  The	  RecB	  motor	  translocates	  in	  a	  5'	  to	  3'	  direction	  on	  the	  ssDNA,	  whereas	  RecD	  motor	  is	  sliding	  in	  3'	  to	  5'	  direction	  on	  the	   opposite	   strand	   but	   in	   the	   same	   overall	   direction.16,17	   RecBCD	   then	   loads	  recombination	   protein	   A	   (RecA;	   RAD51	   homolog)	   onto	   3'-­‐tailed	   ssDNA	   and	   then	  dissociates	   from	   the	   RecA-­‐coated	   ssDNA	   filament,	   showing	   that	   resection	   and	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recombinase-­‐loading	  steps	  are	  coupled.	  In	  the	  RecF	  pathway,	  the	  repair	  of	  an	  ssDNA	  gap	   starts	  with	  a	  5'	   to	  3'	   resection	  by	  RecJ	  nuclease	   (Exo1	  homolog)	   in	   conjuction	  with	  a	  3'	  to	  5'	  RecQ	  helicase.	  The	  ssDNA	  regions	  are	  covered	  with	  single-­‐strand	  DNA	  binding	   protein	   (SSB;	   RPA	   homolog).	   The	   RecFOR	   complex	   consists	   of	   3	   subunits,	  RecF,	  RecO	  and	  RecR	  and	  mediates	   the	  nucleation	  of	  RecA	  onto	  SSB-­‐coated	  ssDNA	  filament	  while	   displacing	   SSB	   at	   the	   same	   time.	   Both	   RecBCD	   and	   RecF	   pathways	  employ	  RuvA,	  RuvB	  and	  RuvC	  to	  resolve	  Holliday	  junction.15,18,19	  	  	  




Figure	  1:	  Pathways	  of	  DSB	  repair	  in	  homologous	  recombination.	  2	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1.2 REGULATION	  OF	  HOMOLOGOUS	  RECOMBINATION	  	  
1.2.1 Rad52	  	  	   Rad52	  is	  a	  key	  protein	  in	  HR	  in	  Saccharomyces	  cerevisiae.	  In	  budding	  yeast,	  Rad52	  loads	   RAD51	   onto	   RPA-­‐coated	   ssDNA	   filament20,21	   and	   anneals	   complementary	  ssDNA	  coated	  with	  RPA.	  The	  first	  of	  yeast	  Rad52	  roles	  is	  similar	  to	  that	  of	  BRCA2	  in	  mammals.	  20,21	  The	  second	  role	  is	  conserved	  in	  evolution	  and	  lies	  in	  its	  necessity	  in	  the	  annealing	  step	  where	  the	  second	  end	  is	  captured	  in	  the	  single-­‐strand	  annealing	  pathway.	   22	   Knowing	   the	   importance	   of	   Rad52	   in	   budding	   yeast,	   it	  was	   surprising	  that	  RAD52	  knockout	  mice	  were	  not	  affected	  in	  homologous	  recombination	  23	  as	  well	  as	  in	  U.	  maydis	  and	  chicken	  cells.	  24	  However,	  its	  importance	  in	  HR	  became	  evident	  in	  
BRCA2-­‐deficient	  human	  cell	  line	  where	  human	  RAD52	  inactivation	  leads	  to	  defective	  HR	   and	   decrease	   of	   RAD51	   foci	   formation	   upon	   treatment	  with	   ionizing	   radiation	  (IR).	  25	  Human	  RAD52	  lacks	  recombination	  mediator	  activity	  in	  in	  vitro	  biochemical	  assays,	   therefore	   it	   is	   thought	   that	   it	   possibly	   synergizes	   with	   RAD51	   paralogs	  (RAD51B,	  RAD51C,	  RAD51D,	  XRCC2,	  and	  XRCC3),	  which	  will	  be	  described	  below.	  A	  hint	   leading	   to	   such	   assumption	   is	   provided	   by	   a	   study	  where	  DT40	   chicken	   cells	  were	  defective	  in	  XRCC3	  function	  after	  RAD52	  inhibition.21,24	  	  
1.2.2 BRCA2	  	  	  	   RAD51	   foci	   accumulate	  at	   ssDNA	  regions	   formed	  after	   resection	  of	  broken	  DNA	  ends.	  However,	  to	  localize	  at	  those	  sites,	  RAD51	  focus	  formation	  requires	  specific	  HR	  factors,	   known	   as	   recombination	  mediators,	   including	  RAD51B,	   RAD51C,	   RAD51D,	  XRCC2,	   XRCC3,	   and	   BRCA2	   32,	   which	   will	   be	   discussed	   below.	   Recombination	  mediators	  have	   indispensables	   roles	   in	   the	  HR,	  where	   they	  promote	   the	   formation	  and	  stabilize	  RAD51	  filaments	  on	  ssDNA	  through	  multiple	  mechanisms.	  	  	   A	   fraction	  of	  breast	  or	  ovarian	  cancers	   is	  associated	  with	  hereditary	  or	  sporadic	  mutations	  in	  BRCA1	  26,	  BRCA2	  (breast	  cancer	  type	  2	  susceptibility	  protein)	  or	  PALB2	  (partner	  and	   localizer	  of	  BRCA2)	  genes.	  Mutations	   in	   these	  genes	   lead	  to	  excessive	  genome	   instability.27,28	   Moreover,	   Brca1-­‐deficient	   mice	   exhibit	   early	   embryonic	  lethality,	  similarly	  to	  Brca2.29	  In	  vivo,	  BRCA1	  and	  BRCA2	  were	  shown	  to	  interact	  with	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each	  other,	  however	  the	  link	  between	  them	  was	  unclear.	  The	  study	  conducted	  by	  Sy	  et	  al.	  27	  describes	  PALB2	  as	  a	  scaffolding	  protein	  amongst	  BRCA1	  and	  BRCA2.	  PALB2	  was	  shown	  to	  directly	  bind	   to	  BRCA1	  via	   the	  coiled-­‐coil	  motif	  and	  also	  serves	  as	  a	  bridging	  protein	  to	  the	  BRCA2-­‐RAD51	  complex.	  PALB2	  interacts	  with	  BRCA2	  via	  its	  C-­‐terminal	  domain,	  specifically	  with	  its	  transactivation	  core	  sequence.	  Furthermore,	  all	   three	  proteins,	  BRCA1,	  BRCA2,	  and	  PALB2	  colocalize	  at	  sites	  of	  DNA	  damage	  as	  nuclear	   foci	   upon	   DNA	   damage.	   Interestingly,	   BRCA1	   acts	   upstream	   of	   PALB2	   as	  BRCA1	  foci	  formation	  is	  unaffected	  by	  disrupting	  the	  interaction	  between	  these	  two	  proteins.	  Conversely,	  PALB2	  is	  a	  compulsory	  factor	  for	  the	  recruitment	  of	  BRCA2	  to	  DNA	   damaged	   sites.	   28,30	   In	   accord,	   BRCA2-­‐defective	   CAPAN-­‐1	   cell	   line	   shows	  inability	  of	  RAD51	  to	  form	  nuclear	  foci,	  however	  such	  phenotype	  was	  not	  observed	  for	  BRCA1,	  where	  the	  foci	  at	  DNA	  damage	  sites	  formed	  normally.31	  	  	   The	  breast	   cancer	   tumor	  suppressor	  BRCA2	   is	  a	  key	  recombination	  mediator	   in	  homologous	   recombination	   in	   high	   eukaryotes.	   Mutations	   in	   the	   BRCA2	   gene	  predispose	   affected	   individuals	   to	   high	   risk	   of	   ovarian	   and	   breast	   cancer	   27,28,	  pancreatic	  cancer,	  and	  other	  tumors	  in	  infants	  suffering	  of	  Fanconi	  anemia.	  33	  	  	   While	   in	  budding	  yeast	  BRCA2's	   function	   is	  supplemented	  by	  Rad52	  and	  BRCA2	  homolog	  is	  missing	  completely	  as	  mentioned	  above,	  several	  BRCA2	  homologs	  can	  be	  found	   in	   other	   species,	   such	   as	   BRCA2	   in	   mice	   (Mus	   musculus),	   BRC-­‐2	   in	   the	  nematode	  Caenorhabditis	   elegans,	   or	   Brh2	   in	   the	   fungus	  Ustilago	  maydis.34	  Human	  BRCA2	  is	  structured	  into	  several	  domains.	  The	  N-­‐terminal	  region	  is	  interacting	  with	  PALB2	  at	  amino	  acids	  between	  21	  and	  39.	  The	  BRC1-­‐8	  repeats	  at	  amino	  acid	  region	  between	  1009	  and	  2083	  are	  RAD51	  binding	  sites	  together	  with	  the	  C-­‐terminal	  TR2	  region.35,36,37	   BRCA2	   also	   possesses	   DNA-­‐binding	   domain	   consisting	   of	   a	   helical	  domain	   (H),	   three	   oligonucleotide	   binding	   (OB)	   folds	   and	   a	   tower	   domain	   (T),	  possibly	   necessary	   for	   binding	   to	   both	   ssDNA	   and	   dsDNA.35,38	   Human	  BRCA2	   also	  has	  a	  Dmc1	  interaction	  site,	  known	  as	  PhePP	  motif,	  a	  26-­‐amino-­‐acid	  residue	  region	  located	  between	   amino	   acid	   residues	   2386	   and	  2411	   (Figure	   2).2	   BRCA2	   interacts	  with	   human	   RPA	   through	   its	   N-­‐terminal	   region	   located	   at	   the	   amino	   acid	   region	  between	   18-­‐105,	   called	   an	   acidic	   transactivation	   domain.39	   Furthermore,	   a	   cancer	  predisposing	   mutation	   Y42C	   in	   BRCA2	   affected	   RPA	   binding,	   pointing	   at	   the	  importance	  of	  interaction.40	  
	   16	  
	  	  
Figure	  2:	  BRCA2	  domain	  structure.	  	  	  	  	   BRCA2	   orchestrates	   the	  HR	  machinery	   through	   the	   interaction	  with	   the	  RAD51	  recombinase.	   It	   helps	   to	   overcome	   inhibitory	   effect	   of	   RPA-­‐bound	   DNA	   and	  promotes	   the	   nucleation	   and	   growth	   of	   RAD51	   on	   the	   ssDNA	   overhang.	   RAD51	   is	  known	  to	  hydrolyze	  ATP	  upon	  DNA	  binding.	  The	  DNA-­‐dependent	  ATPase	  activity	  of	  RAD51	   is	   regulated	   by	   the	   Mg2+	   and	   Ca2+	   cations.	   In	   vitro,	   the	   presence	   of	   Mg2+	  results	  in	  a	  fast	  ATP	  hydrolysis,	  meaning	  that	  ATP	  (RAD51-­‐ATP-­‐ssDNA;	  active	  form)	  is	   quickly	   converted	   into	   ADP	   (RAD51-­‐ADP-­‐ssDNA;	   inactive	   form).	   On	   the	   other	  hand,	   addition	   of	   Ca2+	   slows	   down	   the	   ATP	   hydrolysis	   rate,	   therefore	   keeping	   the	  active	  form	  of	  the	  filament,	   i.e.	  RAD51-­‐ATP-­‐ssDNA.	  Interestingly,	  such	  an	  effect	  has	  not	  been	  shown	  in	  the	  yeast	  Rad51	  counterpart.	  41	  	   Initial	  studies	  focused	  on	  BRCA2	  mechanistic	  function	  in	  HR	  and	  repair	  of	  dsDNA	  breaks	  were	  hampered	  by	  the	  difficulties	  in	  purifying	  the	  full-­‐length	  protein	  due	  to	  its	  size,	  3418	  amino	  acids	  (~384	  kDa).34,42	  In	  2010,	  however,	  three	  different	  groups	  purified	   independently	   the	   full-­‐length	   protein	   and	   provided	   insights	   into	   BRCA2	  function	   in	   vitro.20,34,42	   Purified	   full-­‐length	   BRCA2	   from	   human	   cells	   binds	   both	  ssDNA	  and	  dsDNA	  oligonucleotide	  substrates	  20,	  but	  shows	  a	  strong	  preference	   for	  ssDNA	   substrates,	   including	   3'	   tailed	   and	   5'tailed	   DNA	   oligonucleotides.	   BRCA2	  functions	  in	  the	  HR	  repair	  as	  a	  recruitment	  factor	  of	  RAD51,	  which	  brings	  RAD51	  to	  the	  resected	  ssDNA	  regions.	  This	  is	  a	  crucial	  reaction	  step	  in	  the	  HR	  as	  impairment	  of	  BRCA2-­‐RAD51	   interaction	   leads	   to	   chromosome	   instability	   and	   a	   failure	   to	   repair	  dsDNA	  breaks	  in	  S-­‐phase.43	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   RAD51	  catalyzes	  the	  strand	  exchange	  reaction	  and	  searches	  for	  homology	  regions	  within	  the	  homologous	  DNA	  of	  the	  sister	  chromatid.	  Under	  experimental	  conditions,	  where	  RPA	   is	  not	   covering	   the	  3'	   ssDNA	  overhang,	  RAD51	  can	  perform	   the	   strand	  exchange	  reaction	  by	   itself.	  Additionally,	  RAD51	  must	  be	  pre-­‐bound	   to	  ssDNA	   first	  and	  then	  dsDNA	  is	  added	  to	  the	  reaction.20	  RAD51	  was	  shown	  to	  have	  an	  affinity	  to	  both	   ssDNA	   and	   dsDNA,	   which	   is	   detrimental	   for	   strand	   exchange	   reaction	   as	  binding	  of	  RAD51	  to	  dsDNA	  is	   inhibitory	  and	  strand	  invasion	  cannot	  occur.	  BRCA2	  possesses	  the	  ability	  to	  tackle	  both	  situations	  -­‐	   it	   inhibits	  RAD51	  binding	  to	  dsDNA	  and	  directs	  it	  to	  ssDNA,	  where	  it	  helps	  its	  loading	  onto	  RPA-­‐coated	  ssDNA.	  20,34,42	  	   What	   is	   the	   exact	  mechanism	  of	  BRCA2	  mediator	   function	   in	  promoting	  RAD51	  nucleation	  on	  ssDNA?	  BRCA2	  possesses	  eight	  BRC	  repeats,	  BRC1-­‐8.	  Crystallographic	  studies	   revealed	   that	   BRC4	   repeat	   binds	   RAD51	   through	   several	   conserved	  interaction	   sites,	  namely	  Phe	  1524,	  Ala	  1527,	  Leu	  1545,	   and	  Phe	  1546.45	  This	  was	  later	  shown	  in	  in	  vitro	  assays	  where	  BRC1-­‐8	  and	  BRC4	  interactions	  with	  RAD51	  and	  DNA	  substrates	  were	  investigated.46	  	  	   The	   binding	   of	   RAD51	   to	   dsDNA	   can	   be	   reduced	   by	   the	   BRC4	   repeat	   alone.	  Similarly,	   BRC4-­‐bound	   BRCA2	   stabilized	   RAD51-­‐ssDNA	   nucleofilament	   by	  preventing	  RAD51	  ATP	  hydrolysis	  and	  keeping	  RAD51	  in	  its	  ATP-­‐bound	  form.	  This	  is	  necessary	   for	   strand	   invasion	   in	   later	   stage	   of	   HR.46	   Two	   modes	   of	   action	   were	  identified	  for	  the	  two	  distinct	  BRC	  repeat	  regions.	  BRC1-­‐4	  binds	  free	  RAD51	  unlike	  BRC5-­‐8	   that	   does	   not	   have	   such	   ability.	   BRC5-­‐8,	   on	   the	   other	   hand,	   binds	  RAD51-­‐coated	   ssDNA	  with	   a	   high	   affinity.37,47	   This	   is	   in	   agreement	  with	   previous	   studies	  where	  full-­‐length	  BRCA2	  was	  reported	  to	  bind	  4-­‐6	  RAD51	  molecules.20,42	  	  	   In	  Chatterjee	  et	  al.	  37	  study,	  the	  BRC5-­‐8	  region	  (1596	  to	  2152	  amino	  acid	  region)	  coupled	  to	  DNA-­‐binding	  domain	  located	  at	  2153	  to	  3418	  amino	  acid	  region)	  	  (DBD-­‐BRC5-­‐8)	   revealed	   a	   distinct	   function	   of	   BRC5-­‐8	   to	   that	   of	   BRC1-­‐4	   in	   promoting	  RAD51	  strand	  exchange	  activity.	  And	  it	  was	  also	  shown	  that	  DBD-­‐BRC5-­‐8	  binds,	  thus	  stabilizes,	   RAD51-­‐coated	   filament	  with	   ~1.5-­‐fold	   higher	   affinity	   than	   DBD-­‐BRC1-­‐4	  and	  DBD-­‐BRC1-­‐8	  region.37	  In	  summary,	  BRC1-­‐4	  promotes	  nucleation	  of	  RAD51	  onto	  ssDNA	   by	   reducing	   RAD51's	   ATPase	   activity	   as	   discussed	   above,	   whereas	   BRC5-­‐8	  repeats	   stabilize	   the	   growing	   RAD51-­‐ssDNA	   filament	   and	   promote	   RAD51	   strand	  exchange	  activity.	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   Moreover,	  there	  is	  evidence	  that	  BRCA2	  functions	  not	  only	  in	  HR	  to	  repair	  DSBs,	  but	  it	   is	  also	  involved	  in	  the	  protection	  of	  stalled	  DNA	  replication	  forks	  by	  averting	  the	  degradation	  of	  newly	  synthesized	  DNA	  strand	  by	  MRE11.	  As	  mentioned	  above,	  BRCA2	  possesses	  nine	  interacting	  sites	  with	  RAD51;	  eight	  BRC	  repeats	  in	  the	  central	  part	   and	  TR2	   domain	   (also	   known	   as	   C-­‐ter)	   located	   at	   the	   C-­‐terminus.	  While	   BRC	  repeats	  are	  necessary	  for	  DSB	  repair,	   it	  has	  been	  shown	  that	  TR2/C-­‐ter	  is	  required	  for	   replication	   fork	   protection.	   Specifically,	   if	   the	  BRCA2	   is	  missing	   the	  TR2/C-­‐ter,	  MRE11	   degrades	   the	   nascent	   strand	   of	   a	   stalled	   DNA	   replication	   fork.	   Such	  degradation	  can	  be	  reduced	  by	  introduction	  of	  the	  MRE11-­‐inhibitor	  mirin.	  Therefore	  BRCA2's	   C-­‐terminal	   TR2/C-­‐ter	   is	   involved	   in	   the	   protection	   of	   stalled	   replication	  forks,	   a	   mechanism	   differing	   from	   the	   traditionally	   known	   DSB	   repair33,	   and	   the	  function	  of	  which	  has	  yet	  to	  be	  determined.	  	  	  	  
1.2.3 RAD51	  PARALOGS	  	  	   In	  Saccharomyces	  cerevisiae,	  Rad55	  and	  Rad57	  were	  initially	  the	  only	  two	  RAD51	  paralogs	  identified	  in	  the	  budding	  yeast.	  However,	  later	  it	  was	  shown	  that	  two	  other	  proteins,	   Csm2	   and	   Psy3,	   belong	   to	   the	   Rad51	   paralogs	   family.21,48,49	   Rad55	   and	  Rad57	  form	  a	  heterodimer,	  while	  Csm2	  and	  Psy3	  bind	  two	  Shu	  proteins	  (Shu1	  and	  Shu2),	   resulting	   in	   the	  Shu	  complex.49	  The	  Rad51	  paralogs	   from	  the	  budding	  yeast	  are,	   similarly	   as	   human	   Rad51	   paralogs,	   essential	   in	   recombination.	   Mutations	   in	  these	  proteins	  lead	  to	  chromosomal	  instability.50	  Rad55-­‐Rad57	  is	  a	  mediator	  protein	  that	   forms	   a	   complex	   with	   Rad51	   bound	   to	   ssDNA	   and	   stabilizes	   Rad51-­‐ssDNA	  filament	   by	   inhibiting	   the	   Srs2	   translocase/helicase	   activity,	   which	   would	   be	  otherwise	  stimulated	  by	  Rad51	  coated	  ssDNA	  filament	  formation.	  Therefore	  Rad55-­‐Rad57	  protects	  newly	  nucleated	  Rad51	  filament	  on	  the	  ssDNA.21	  However,	  to	  allow	  Rad51	  to	  nucleate	  onto	  RPA-­‐coated	  ssDNA,	  Rad51	  requires	  help	  of	  additional	  factors	  to	   overcome	   the	   inhibitory	   effect	   of	   RPA.	   In	   vitro,	   the	   Shu	   complex	   together	   with	  Rad55-­‐Rad57	  and	  Rad52	  promote	  Rad51	  strand	  exchange	  reaction	  in	  the	  presence	  of	   RPA.	   Mutation	   in	   the	   csm2-­‐F46	   allele	   impairs	   interaction	   of	   the	   complex	   with	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Rad55	  resulting	  in	  an	  inability	  to	  promote	  Rad51-­‐ssDNA	  filament	  formation	  in	  vitro	  and	  in	  a	  defective	  HR	  in	  vivo.49	  	   Alongside	  BRCA2,	  five	  other	  human	  recombination	  mediators,	  all	  members	  of	  the	  
RAD51	   gene	   family,	   are	   involved	   in	   HR.	   These	   are	   RAD51B	   (RAD51L1),	   RAD51C	  (RAD51L2),	   RAD51D	   (RAD51L3),	   XRCC2,	   and	   XRCC3.50	   Individual	   mutants	   of	   each	  RAD51	  paralog	  are	  severely	  impaired	  in	  RAD51	  focus	  formation	  upon	  DNA	  damage	  induced	   by	   ionizing	   radiation	   (IR),	   pointing	   towards	   their	   crucial	   role	   in	   HR.51	  RAD51	  paralogs	  share	  around	  20-­‐30	  %	  identity	  of	  amino	  acids	  with	  RAD51,	  however	  all	   are	   lacking	   recombinase	  activity	  per	  se.52,53	  Mutants	  generated	   in	   chicken	  DT40	  cells,	  rad51c,	  rad51d,	  xrcc2,	   and	  xrcc3	  were	  all	  defective	   in	  RAD51	   focus	   formation	  and	   were	   sensitive	   to	   cisplatin	   treatment.	   This	   was	   partially	   overcome	   by	  overexpressing	   RAD51,	   which	   could	   to	   some	   extent	   supplement	   the	   missing	  paralog's	  function.51	  This	  suggested	  that	  the	  RAD51	  paralogs	  function	  in	  conjunction	  with	   RAD51.	   Interestingly,	   individual	   rad52	   and	   xrcc3	   mutants	   were	   viable	   and	  displayed	  no	  hindrance	  in	  the	  growth,	  however	  the	  double	  mutant	  rad52	  xrcc3	  was	  non-­‐viable.24	   None	   of	   the	   paralogs	   self-­‐interacts	   such	   as	   RAD51,	   which	   forms	  heptamers	   in	   solution.2,52	   However,	   the	   paralogs	   form	   several	   different	   complexes	  within	   each	   other.	   In	   HeLa	   cells,	   RAD51B-­‐RAD51C-­‐RAD51D-­‐XRCC2	   (BCDX2)	   and	  RAD51C-­‐XRCC3	   (CX3)	   were	   detected.	   Human	   recombinant	   RAD51C	   and	   XRCC3	  interact	  directly	  as	  well	  as	  RAD51B	  and	  RAD51C.54,55	  Furthermore,	  RAD51D	  forms	  a	  complex	   with	   XRCC2.56	   Shu1	   is	   a	   homolog	   of	   XRCC2	   and	   Psy3	   is	   a	   homolog	   of	  RAD51D.	   Furthermore,	   Shu2	   is	   homologous	   with	   human	   SWS1,	   a	   protein,	   which	  interacts	  with	  RAD51,	   as	  well	   as	  with	  RAD51	   paralogs.57	   The	   function	   of	   SWS1	   in	  human	  cells	  is	  yet	  to	  be	  determined.	  	   Depletion	  of	  XRCC3	  results	  in	  reduced	  HR,	  but	  RAD51	  foci	  form	  normally	  at	  sites	  of	  DNA	  damage.	  RAD51	   focus	   formation	  was	  also	  unaffected	   in	  XRCC3-­‐/-­‐	   colorectal	  cells.	   Furthermore,	   simultaneous	   depletion	   of	   RAD51C	   and	   XRCC3	   (CX3)	   did	   not	  affect	  RAD51	  focus	  formation	  either,	  suggesting	  a	  role	  for	  CX3	  complex	  downstream	  of	  RAD51	  binding	   to	   ssDNA.	   In	  accord,	  after	   induction	  of	  DNA	  damage,	  XRCC3	   foci	  colocalized	   with	   RAD51,	   however	   they	   persisted	   even	   after	   the	   disappearance	   of	  RAD51	  foci.57	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RAD51B	   and	   RAD51C	   form	   a	   heterocomplex	   and	   represent	   the	   known	   human	  homologs	   of	   the	   Rad55-­‐Rad57	   recombination	   mediator	   complex	   found	   in	   the	  budding	  yeast	  S.	  cerevisiae.55	  Coprecipitation	  experiments	  revealed	  that	  RAD51B	  and	  RAD51C	   form	   a	   stable	   protein	   complex	   and	   recombinant	   human	   RAD51B	   and	  RAD51C	  proteins	  purified	  from	  Sf9	  insect	  cell	  interact	  directly	  as	  well.54	  Similarly	  to	  BRC1-­‐4,	   purified	   RAD51B-­‐RAD51C	   complex	   binds	   ssDNA	   with	   a	   high	   affinity	   and	  shows	  low	  binding	  to	  dsDNA.	  Furthermore,	  RAD51B-­‐RAD51C	  shows	  ATPase	  activity	  upon	  binding	  to	  ssDNA	  and	  promotes	  RAD51	  strand	  exchange	  activity,	  however	  the	  complex	   alone	   cannot	   overcome	   RPA	   inhibitory	   effect	   sufficiently.	   This	   step	   likely	  requires	   other	   RAD51	   paralogs.54	   Purified	   BCDX2	   complex	   was	   shown	   to	  preferentially	   bind	   ssDNA,	   specifically	   ssDNA	   nicks	   in	   dsDNA	   and	   displays	   ATP-­‐hydrolysis	  activity	  as	  RAD51.	  Furthermore,	  RAD51C-­‐RAD51D	  complex	  interacts	  with	  XRCC2	   via	   RAD51D	   in	   yeast	   two-­‐hybrid	   system.58,59	   RAD51D	   also	   binds	   DNA	   and	  possesses	  ATPase	  activity	  stimulated	  upon	  binding	  to	  ssDNA	  and	  dsDNA	  and	  forms	  a	  heterodimer	  with	  XRCC2.53,59	  Interestingly,	  in	  Caenorhabditis	  elegans,	  Rad51	  paralog	  complex	  RFS-­‐1/RIP-­‐1	  binds	  ssDNA	  but	  not	  dsDNA	  and	  also	  stimulates	  Rad51	  strand	  exchange	  in	  vitro.	  In	  vivo	  analyses	  showed	  a	  necessity	  of	  RFS-­‐1/RIP-­‐a	  for	  Rad51	  foci	  formation	  in	  HR	  60,	  which	  is	  reminiscent	  of	  human	  RAD51	  paralogs.	  	  
1.2.4 RAD54	  	  	  	   RAD54	  translocase	  is	  a	  protein	  belonging	  to	  the	  RAD52	  epistasis	  group,	  a	  class	  of	  enzymes	   sharing	   common	   features,	   such	   as	   mutation	   in	   any	   of	   them	   results	   in	  defects	  in	  HR,	  as	  well	  as	  in	  sensitivity	  to	  DNA-­‐damaging	  agents.8,61	  RAD54's	  function	  in	   HR	   has	   mainly	   been	   characterized	   biochemically.	   RAD54	   is	   a	   multifunctional	  translocase	   involved	   in	   all	   three	   steps	   of	   HR,	   pre-­‐synapsis,	   synapsis,	   and	   post-­‐synapsis.8	   In	   pre-­‐synapsis,	   RAD54	  displaces	  RAD51	   from	  dsDNA	   in	   order	   to	   allow	  Rad51	  to	  bind	  ssDNA	  instead.	  In	  synapsis,	  RAD54	  stimulates	  DNA	  strand	  exchange	  in	  the	  presence	  of	  Ca2+,	   stimulates	  DNA	  heteroduplex	  extension	  promoted	  by	  RAD51,	  and	   also	   can	   translocate	   along	   dsDNA	   using	   the	   energy	   of	   ATP	   hydrolysis.	   And	  finally,	  in	  post-­‐synapsis,	  Rad54	  promotes	  branch	  migration	  of	  Holliday	  junction	  in	  an	  ATP-­‐dependent	  manner.62	  In	  vivo,	  RAD54	  forms	  nuclear	  foci	  at	  sites	  of	  DNA	  damage	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and	   colocalizes	   with	   RAD51	   at	   such	   sites.63	   	   Mouse	   embryonic	   stem	   cells	   lacking	  
RAD54	  are	  sensitive	  to	  ionizing	  radiation	  and	  display	  defects	  in	  HR,	  similarly	  to	  yeast	  
RAD54	   mutants.	   On	   the	   other	   hand,	  RAD54	   knockout	  mice	   are	   not	   sensitive	   to	   IR	  treatment,	   but	   show	   sensitivity	   to	  mitomycin	   C,	   an	   interstrand	   DNA	   cross-­‐linking	  agent.63	   In	   humans,	   there	   two	   RAD54	   homologs,	   RAD54	   and	   RAD54B.14	   The	   data	  suggest	   that	   their	   function	   in	   HR	   is	   likely	   redundant	   as	   they	   are	   both	   double-­‐stranded	  DNA-­‐dependent	  ATPases,	  can	   translocate	  along	  DNA,	  and	  display	  double-­‐helix-­‐opening	  activities.63	  RAD54B	  is	  thought	  to	  be	  a	  homolog	  of	  yeast	  Rdh54	  (also	  known	   as	   Tid1)	   based	   on	   amino	   acid	   sequence	   homology.	   However,	   functional	  studies	   hint	   towards	   a	   possibility	   that	   this	   is	   not	   a	   true	   RAD54B	   homolog.63	  Rdh54/Tid1	   interacts	   with	   Dmc1	   during	   meiosis	   as	   shown	   for	   RAD54B.14,64	  Biochemically,	   Rdh54	  possesses	  ATPase	   activity	   and	   similarly	   as	  RAD54	  promotes	  RAD51	   strand	   invasion/D-­‐loop	   formation.	   However,	   rad54	   and	   rdh54	   phenotypes	  differ	   in	   response	   to	   DNA	   damaging	   agents.	   rad54	   mutants	   are	   sensitive	   to	   the	  treatment	   with	   alkylating	   agent	   methyl	   methansulfonate	   (MMS)	   unlike	   rdh54.	  Furthermore,	  RAD54	  and	  RDH54	   likely	  have	  to	  some	  extent	  overlapping	  function	  in	  meiosis,	  as	  double	  mutants	  rad54	  rdh54	  resulted	  in	  lower	  sporulation	  efficiency	  and	  spore	  viability	  in	  comparison	  to	  individual	  mutants.63	  	  
1.2.5 Hop2-­‐Mnd1	  complex	  	  	   Dmc1	  and	  Rad51	  are	  both	  necessary	  factors	  for	  successful	  meiotic	  recombination.	  Unlike	   Rad51,	   Dmc1	   is	   only	   expressed	   in	   meiosis.	   Dmc1	   is	   known	   to	   form	   an	  octameric	   complex,	   resembling	   a	   ring	   and	   such	   structure	   is	   then	  bound	   to	  Rad51-­‐coated	  ssDNA	  filament.	  In	  fact,	  Rad51	  is	  required	  in	  order	  to	  load	  Dmc1	  to	  a	  resected	  ssDNA	   overhang	   as	   rad51	  mutants	   resulted	   in	   an	   inability	   of	   Dmc1	   to	   bind	   to	   the	  sites	   of	   the	   breaks.	   Similarly	   to	   Rad51,	   Dmc1	   can	   also	   catalyze	   strand	   exchange	  reactions	   in	   vitro,	   resulting	   in	   a	   D-­‐loop	   formation.14	   Rad51/Dmc1	   together	   with	  Hop2-­‐Mnd1	  promote	   strand	   invasion	   and	   align	   the	   3'	   ended	   ssDNA	  overhang	   to	   a	  homologous	   region.	   Rad51/Dmc1	   can	   catalyze	   such	   reaction	   alone,	   however	   in	   a	  rather	  slow	  and	  ineffective	  manner.12	  Hop2-­‐Mnd1	  complex	  is	  a	  known	  evolutionarily	  conserved	   cofactor	   of	   the	   Dmc1	   recombinase	   in	   meiotic	   cells	   in	   S.	   cerevisiae.	  Furthermore,	  it	  has	  been	  shown	  that	  mutations	  in	  the	  HOP2	  and	  MND1	  genes	  result	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in	   a	   similar	   phenotype	   as	  DMC1,	   i.e.	   inability	   to	   promote	   DNA	   pairing	   (synapsis)	  between	  homologs,	  and	  such	  phenotype	  can	  be	  partially	  rescued	  by	  overexpressing	  Rad51.12,14	   Recent	   studies,	   however,	   revealed	   Hop2-­‐Mnd1	   importance	   in	   somatic	  cells	   in	  higher	  eukaryotes	  as	  well.65	  Hop2	  and	  Mnd1	   form	  a	  Y-­‐shaped	  heterodimer	  possessing	   two	  dsDNA-­‐binding	  domains	  at	   the	  N-­‐terminus	  and	  one	  ssDNA-­‐binding	  domain	   at	   the	  C-­‐terminus	   of	   the	   complex.	   Two	  RAD51/DMC1	   interaction	   sites	   are	  located	   at	   the	   C-­‐terminus	   as	   well	   on	   both	   protein	   complex	   subunits.	   Hop2-­‐Mnd1	  complex	  binds	  with	  its	  C-­‐terminus	  to	  ssDNA	  and	  via	  RAD51/DMC1	  interaction	  sites	  stabilizes	  the	  RAD51-­‐ssDNA	  filament.	  The	  V-­‐shaped	  N-­‐terminus	  of	  the	  complex	  then	  captures	   the	   dsDNA	   and	   forms	   a	   synaptic	   complex	   enabling	   RAD51	   to	   search	   for	  homology	  regions	  within	  captured	  DNA	  duplex.65	  	  	  	  
1.3 MMS22L-­‐TONSL	  	  
1.3.1 YEAST	  Mms22	  	  First	  reports	  about	  Saccharomyces	  cerevisiae	  Mms22	  are	  dated	  back	  to	  1977.	  In	  this	  study,	   Prakash	   and	   Prakash	   66	   performed	   screening	   that	   identified	   22	   mutants	  sensitive	  to	  methylmethane	  sulfonate	  (MMS),	  an	  alkylating	  agent	  known	  for	  blocking	  DNA	  replication	  forks.	  Whilst	  other	  mms	  mutants	  were	  also	  sensitive	  to	  UV,	  X-­‐rays,	  or	   both,	   five	   mutants	   showed	   sensitivity	   only	   to	   MMS,	   namely	  mms1-­‐4,	  mms2-­‐1,	  
mms4-­‐1,	  mms5-­‐2,	  and	  mms22-­‐1.	  66	  However,	  such	  mutants	  were	  not	  of	  any	  interest	  in	  that	   study,	   therefore	   the	  mms1	   and	  mms22	   mutants	   escaped	   further	   attention	   for	  many	  subsequent	  years.	  Mms22	  together	  with	  cullin	  Rtt101	  and	  mms1	  form	  a	  Cul4(Dbd1)-­‐like	  E3	  ubiquitin	  ligase	  67,	  where	  it	  serves	  as	  substrate-­‐specific	  adaptor.	  Mms22	  is	  linked	  to	  Rtt101	  via	  Mms1,	  similarly	  as	  human	  DDB1	  (damage-­‐specific	  DNA	  binding	  protein	  1).67,68	  	  	  However,	   later,	   Duro	   et	   al.	   69	   uncovered	   that	   Mms22	  might	   be	   acting	   as	   a	   repair	  factor	  in	  HR.	  Based	  on	  these	  studies	  it	  is	  not	  clear,	  whether	  Mms22	  is	  a	  link	  between	  HR	  and	  histones.	  Below,	  I	  will	  focus	  mainly	  on	  Duro	  et	  al.	  69	  study,	  which	  is	  relevant	  to	  my	  research.	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   The	   sensitivity	  of	  mms22	   and	  mms1	  mutants	   to	  agents	  blocking	   replication	   fork	  progression	  suggested	  their	  potential	  involvement	  in	  the	  repair	  of	  stalled	  or	  broken	  replication	  forks.	  To	  this	  point,	  Duro	  et	  al.	  69	  investigated	  Mms22	  and	  Mms1	  mutants	  and	   their	   role	   within	   the	   HR	   repair	   pathway.	   HR	   needs	   a	   template	   to	   copy	   the	  missing	   information	   from.	   Such	   scenario	   happens	   only	   in	   the	   S-­‐phase	   or	   the	   G2-­‐phase	  of	  the	  cell	  cycle.	  Indeed,	   in	  cells	  synchronized	  in	  G1-­‐phase	  and	  then	  released	  into	   S-­‐phase,	   those	   cells	   lacking	   MMS1	   and	   MMS22,	   as	   well	   as	   RAD51	   showed	  marked	  reduction	  of	  HR	  (unequal	  sister	  chromatid	  exchange;	  uSCE)	  after	  treatment	  with	  MMS	  in	  comparison	  with	  parental	  cells.	  Similar	  effect	  was	  observed	  when	  those	  cells	  were	  treated	  with	  camptothecin	  (CPT),	  a	  topoisomerase	  I	  inhibitor	  that	  causes	  ssDNA	  breaks	  and	  stalls	  DNA	  replication	  forks.70	  DNA	  template	  for	  HR	  can	  be	  found	  not	   only	   in	   sister	   chromatids	   but	   also	   in	   homologous	   chromosomes.	   69	   Treatment	  with	  different	  concentrations	  of	  MMS	  resulted	  in	  a	   lower	  frequency	  of	  heteroallelic	  recombination	   in	   cells	   lacking	   MMS22	   and	   MMS1.	   Therefore	   MMS22	   and	   MMS1	  function	  upon	  replication	  fork	  stalling,	  and	  are	  required	  for	  HR	  repair	  utilizing	  as	  a	  template	  either	  sister	  chromatid	  or	  homologous	  chromosome.	  
	   MMS22	  and	  MMS1	  are	  clearly	  involved	  in	  the	  repair	  of	  ssDNA	  breaks	  but	  are	  they	  also	   required	   for	   HR	   induced	   by	   dsDNA	   breaks	   formed	   upon	   DNA	   damage?	   To	  answer	  this	  question,	  Duro	  et	  al.	  69	  went	  on	  and	  treated	  the	  cells	  with	  galactose	  that	  induced	  HO	  endonuclease,	  which	  subsequently	  created	  DSBs.	  As	  expected,	  dramatic	  increase	  in	  the	  frequency	  of	  HR	  was	  observed	  in	  wild-­‐type	  cells,	  which	  could	  repair	  the	   dsDNA	   break	   but	   in	   contrast	   very	   low	   frequency	   in	   cells	   lacking	   RAD51.	   But	  surprisingly,	  in	  cells	  lacking	  MMS22	  and	  MMS1,	  the	  frequency	  of	  HR	  was	  unaffected.	  These	   results	  were	   further	   confirmed	   by	   treating	   the	   same	  mutants	  with	   ionizing	  radiation	  (IR),	  which	  is	  known	  for	  giving	  rise	  to	  DSBs.69,71	  Indeed,	  MMS1	  and	  MMS22	  lacking	  cells	  were	  unaffected	  by	  this	   treatment,	  resulting	   in	  a	  similar	  phenotype	  as	  described	   above,	   i.e.	   frequency	   of	   HR	   was	   almost	   as	   high	   as	   in	   wild-­‐type	   cells.	  Collectively,	   these	   results	   indicate	   a	   possible	   function	   of	  MMS1	   and	  MMS22	   upon	  replication	   fork	   stalling	   but	   not	   in	   the	  HR	   initiated	   by	  DSBs.69	   However,	   the	   exact	  mechanism	  of	  the	  function	  of	  Mms22	  and	  Mms1	  remains	  to	  be	  elucidated.	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1.3.2 HUMAN	  MMS22L-­‐TONSL	  	  	  	   Homologous	  recombination	  (HR)	  represents	  an	  essential	  process	  that	  is	  required	  for	  the	  progression	  and	  completion	  of	  DNA	  replication	  of	  mammalian	  cells.	  Although	  HR	   has	   been	  mostly	   studied	   in	   the	   context	   of	   direct	   DSB	   repair,	   these	   lesions	   are	  rather	  rare	  and	  are	  primarily	  repaired	  by	  non-­‐homologous	  end	  joining	  pathway.1	  In	  contrast,	   the	   primary	   role	   of	   HR	   is	   the	   repair	   of	   single-­‐strand	   DNA	   breaks	   (SSBs)	  encountered	  by	  DNA	  replication	  machinery,	  to	  restart	  stalled	  replication	  forks	  and	  to	  repair	   ssDNA	   gaps	   behind	   replication	   forks.	   These	   lesions	   cannot	   be	   repaired	   by	  non-­‐homologous	   end-­‐joining	   mechanisms,	   and	   are	   thought	   to	   be	   much	   more	  frequent	  than	  direct	  DSBs.	  	   As	  already	  mentioned	  in	  the	  previous	  chapters,	  mechanistically,	  HR	  is	  initiated	  by	  5'	   to	   3'	   resection	   resulting	   in	   large	   3'-­‐terminated	   ssDNA	   overhang,	   which	   is	   then	  covered	  with	  RPA	  to	  prevent	  the	  formation	  of	  secondary	  structures.	  However,	  RPA-­‐coated	   ssDNA	   filament	   results	   in	   an	   inhibitory	   effect	   on	   RAD51,	   showing	   the	  necessity	  of	  a	  recombination	  mediator	  to	  help	  load	  RAD51	  onto	  RPA-­‐coated	  ssDNA	  filament.	   Below,	   I	   will	   discuss	   recent	   studies	   69,71-­‐73,	   which	   show	   that	   MMS22L-­‐TONSL	  might	  represent	  a	  novel,	  yet	  uncharacterized	  recombination	  mediator	  that	  is	  distinct	  from	  factors	  described	  in	  chapter	  1.2.	  	  
1.3.2.1 Identification	  of	  the	  MMS22L-­‐TONSL	  complex	  	  	   Given	   the	   fact	   that	   Mms22	   in	   yeast	   is	   a	   crucial	   part	   of	   the	   repair	   machinery	  initiated	   upon	   replication	   fork	   perturbation/replication	   fork	   stalling,	   it	   was	  intriguing	   whether	   this	   protein	   is	   evolutionarily	   conserved.	   In	   2010,	   four	  independent	   groups	   described	   the	   identification	   of	   a	   human	   homolog,	  MMS22L.71,72,73,74	  Specifically,	  Duro	  et	  al.	  71	  performed	  multiple	  sequence	  alignment	  analyses	  and	  found	  an	  evolutionarily	  conserved	  region	  between	  yeast	  Mms22	  (781-­‐920)	   and	   human	   (373-­‐535)	   C6ORF167.	   Since	   this	   was	   the	   only	   similarity	   found	  between	  these	  two	  proteins,	  the	  human	  ortholog	  was	  called	  Mms22-­‐like	  (MMS22L).	  Furthermore,	   search	   for	   potential	   interacting	   partners	   of	   MMS22L	   by	  immunoprecipitation	  studies	  identified	  another	  human	  protein,	  NFKBIL2.	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   NFKBIL2	   shares	   several	   similarities	  with	   TONSOKU	   found	   in	   plants,	   hence	   it	   is	  called	   Tonsoku-­‐like	   (TONSL).	   They	   both	   contain	   multiple	   protein	   interaction	  modules	  such	  as	  tetratricopeptide	  (TPR)	  repeats,	  ankyrin	  (ANK)	  repeats,	  leucin-­‐rich	  repeats	   (LRR),	   and	   PB1	   ubiqutin-­‐like	   domain.	   The	   domain	   structure	   reveals	   a	  potential	  function	  of	  TONSL	  as	  a	  scaffolding	  protein.	  Such	  protein	  usually	  serves	  as	  bridge/scaffold	   by	   interacting	   with	   other	   proteins,	   meaning	   that	   TONSL	   likely	  interacts	  with	  other	  proteins	  and	  not	  only	  with	  MMS22L.75,	  76,77	  	  	  
1.3.2.2 MMS22L-­‐TONSL	  complex	  interacts	  with	  proteins	  involved	  in	  DNA	  replication	  	  	   Mass	  spectrometry	  analyses	  revealed	  that	  MMS22L	  and	  TONSL	  interact	  with	  each	  other	   in	  vivo.71,72	  In	  accord,	  depletion	  of	  one	  protein	  negatively	  affected	  the	  protein	  levels	  of	  the	  other	  protein	  and	  vice	  versa,	  indicating	  that	  MMS22L-­‐TONSL	  interaction	  is	  indispensable	  for	  mutual	  protein	  stability.71	  	  	   Furthermore,	   MMS22L-­‐TONSL	   interacts	   with	   RPA	   (RPA1	   and	   RPA3	   subunits),	  MCM	   (minichromosome	  maintenance	   protein	   complex)	   helicase	   (MCM2,	   -­‐4,	   -­‐6,	   -­‐7)	  71,72,	   histone	   chaperone	  FACT	   (facilitates	   chromatin	   transcription)	   complex	   and	   its	  subunits	  SUPT16H	  and	  SSRP1	  72,	  ASF1A	  and	  ASF1B	  histone	  chaperones	  71,	  histones	  H2A,	  H2B	  71,	  and	  H3.1	  71,78	   (Figure	  3A).	  Moreover,	   interaction	  between	  TONSL	  and	  MCM	  is	  facilitated	  via	  TRP	  repeats	  located	  at	  the	  N-­‐terminus	  of	  TONSL	  with	  help	  of	  ANK	  repeats,	  whereas	  TONSL-­‐MMS22L	  interaction	  is	  mediated	  via	  C-­‐terminus	  of	  the	  TONSL	   where	   LRR	   repeats	   are	   located	   (Figure	   3B).73	   Surprisingly,	   unlike	   yeast	  Mms22,	  no	  interaction	  with	  cullins	  or	  peptides	  derived	  from	  DDB1	  (damage-­‐specific	  DNA	   binding	   protein	   1)	   was	   detected,	   suggesting	   that	   MMS22L	   is	   structured	  differently	  than	  the	  yeast	  homolog	  71,72,	  and	  that	  human	  MMS22L	  will	  not	  be	   likely	  involved	   in	  protein	  ubiquitylation.	  The	  MMS22L-­‐TONSL	   interaction	  data	  altogether	  suggest	   a	   strong	   link	   with	   DNA	   replication,	   where	   the	   MMS22L-­‐TONSL	   complex	  might	  play	  a	  role.	  	  





Figure	  3:	  	  MMS22L-­‐TONSL.	  
A-­‐	   MMS22L-­‐TONSL	   interacting	   partners.	   B-­‐	   TONSL's	   interacting	   domains.	   C	   -­‐	  Possible	  function	  of	  MMS22L-­‐TONSL	  as	  a	  recombination	  mediator	  upon	  replication	  fork	  collapse	  (Adapted	  from	  Duro	  et	  al.71,	  O'Donnel	  et	  al.72,	  and	  Campos	  et	  al.78).	  
1.3.2.3 Possible	  function	  of	  MMS22L-­‐TONSL	  in	  homologous	  recombination	  	  	   Intriguing	   question	   was	   whether	   MMS22L-­‐TONSL	   has	   a	   similar	   function	   as	  Mms22	  in	  yeast.	  To	  investigate	  that,	  Duro	  et	  al.	  71	  depleted	  either	  MMS22L	  or	  TONSL,	  which	  led	  to	  elevated	  levels	  of	  DSBs,	  marked	  as	  53BP1	  and	  γ-­‐H2AX	  subnuclear	  foci,	  even	   without	   introducing	   the	   DNA	   damaging	   agents.71,72	   CPT,	   HU,	   MMS,	   and	  ultraviolet	  13	   light	  can	   induce	  replication-­‐associated	  ssDNA	  breaks.	  Treatment	  with	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such	   DNA	   damaging	   agents	   resulted	   in	   accumulation	   of	  MMS22L	   and	   TONSL	   foci,	  hinting	  that	  MMS22L-­‐TONSL	  repairs	  stalled	  (or	  broken)	  replication	  forks.72	  	   In	  yeast,	  as	  mentioned	  above,	  Mms22	  was	  required	  for	  HR	  repair	  upon	  replication	  fork	  stalling	  but	  not	  for	  HR	  induced	  by	  DSBs.	  	  	   Such	   observation	   was	   further	   confirmed	   in	   the	   following	   experiment,	   where	  depletion	   of	   MMS22L	   or	   TONSL	   did	   not	   affect	   RPA	   foci	   formation	   upon	   CPT	  treatment,	   although	   these	   cells	   showed	   a	   recovery	  delay	   71	   72,	  which	  points	   to	   the	  problem	  downstream	  of	  resection.	  	   Ataxia	   telangiectasia	   mutated-­‐	   and	   Rad3-­‐related	   (ATR)	   signaling	   pathway	  predominantly	   responds	   to	   replication	   fork	   stalling	   and	   is	   recruited	   to	   ssDNA	  regions/lesions	   covered	   by	   RPA.	   ATR	   then	   signals	   the	   DNA	   damage	   by	  phophorylating	  CHK1	  kinase	  to	  prevent	  a	  collapse	  of	  replication	  fork	  during	  S-­‐phase	  of	  the	  cell	  cycle.	  79,80,71,81,82	  Depletion	  of	  either	  MMS22L	  or	  TONSL	  together	  with	  ATR	  sensitized	  cells	  to	  drugs	  hydroxyurea	  (HU),	  cisplatin	  and	  to	  ionizing	  radiation,	  which	  are	   known	   to	   interfere	   with	   progression	   of	   the	   replication	   fork	   machinery.71	  Moreover,	  MMS22L	  depletion	  led	  to	  the	  accumulation	  of	  cells	  in	  G2-­‐phase	  of	  the	  cell	  cycle	   after	   the	   release	   of	   CPT.72	   	   Such	   event	   was	   further	   followed	   by	   the	  phosphorylation	   of	   the	   CHK1	   kinase	   on	   serine	   317	   (S317)	   72,	   demonstrating	   the	  checkpoint	  activation	  as	  a	  response	  to	  DNA	  damage	  and	  replication	  fork	  stalling.82	  	  	   Indeed,	  depletion	  from	  MMS22L	  and	  TONSL	  resulted	  in	  a	  reduction	  of	  RAD51	  foci	  and	  RAD51	  foci	  focus	  formation	  was	  severely	  affected	  after	  treatment	  with	  CPT	  and	  IR	   72,	   meaning	   that	   MMS22L-­‐TONSL	   is	   factor	   acting	   upstream	   of	   RAD51	   foci	  formation.	  Interestingly,	  depletion	  of	  MMS22L	  or	  TONSL	  resulted	  in	  elevated	  levels	  of	  53BP1	  foci	  similarly	  to	  RAD51	  paralogs,	  such	  as	  RAD51C	  and	  XRCC3.	  	   The	   final	   step	  was	   to	   investigate	   the	   involvement	  of	  MMS22L-­‐TONSL	   in	  DR-­‐GFP	  reporter	  assay,	  a	  common	  tool	  to	  study	  HR	  in	  mammalian	  cells.	  I-­‐SceI	  endonuclease	  cuts	  at	  rare-­‐sites	  and	  creates	  DSBs.	  Successfully	  repaired	  DSBs	  by	  HR	  can	  be	  easily	  detected	  by	  GFP	  signal.83	  Interestingly,	  downregulation	  of	  RAD51	  resulted	  in	  about	  96%	   reduction	   of	   GFP-­‐positive	   cells	   and	   downregulation	   of	   both	   MMS22L	   and	  TONSL	  showed	  around	  60%	  reduction	  in	  GFP-­‐positive	  cells.72	  	  	   This	  suggests,	  that	  MMS22L-­‐TONSL	  complex	  facilitates	  RAD51	  loading	  and	  acts	  as	  a	  recombination	  mediator	  in	  HR	  (Figure	  3C),	  similarly	  as	  RAD51	  paralogs	  or	  BRCA2	  (Figure	   4).	   Furthermore,	   depletion	   of	   neither	   MMS22L	   nor	   TONSL	   affected	   the	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stability	   of	   RAD51	   paralogs	   RAD51C	   and	   XRCC3	   71,	   and	   BRCA272,	   suggesting	   that	  MMS22L-­‐TONSL	  promotes	  RAD51	  loading	  in	  a	  distinct	  manner.	  	  	  	  	  	  	  
	  	  	  
Figure	  4:	  Potential	  HR-­‐mediated	  fork	  repair	  of	  stalled	  and	  collapsed	  replication	  fork	  by	  MMS22L-­‐TONSL	  (Adapted	  from	  Piwko	  et	  al.	  84).	  	  	  	  	  	  
1.4 LINKS	  BETWEEN	  RECOMBINATION,	  DISEASE	  AND	  CANCER	  	  
1.4.1 Hereditary	  versus	  sporadic	  cancers	  	  	   Genome	  instability	  and	  mutations	  are	  hallmarks	  of	  cancer.	  Germline	  mutations	  in	  tumor	  suppressor	  genes	  lead	  to	  a	  hereditary	  threat	  of	  developing	  cancer.85,86	  On	  the	  other	  hand,	   'sporadic	  cancers'	  arise	  from	  acquired	  mutations.	  Sporadic	  cancers	  can	  for	  example	  arise	  from	  a	  mutational	  or	  epigenetic	  inactivation.	  Example	  of	  epigenetic	  inactivation	   was	   described	   in	   case	   of	   BRCA1.	   Such	   event	   is	   a	   result	   of	   aberrant	  methylation	  of	  cytosine	  residues	   in	  a	  CpG	   island,	  which	   is	   located	   in	   the	  vicinity	  of	  the	   transcription	  start	  site	  of	   the	  gene.	  DNA	   is	   then	  more	  densely	  packaged	  by	   the	  histones	   and	   therefore	  may	   lead	   to	   a	   silencing	   of	   the	   transcription	   of	   the	   affected	  gene.86	  Both	  sporadic	  and	  hereditary	  cancers	  can	  be	  a	  result	  of	  aberrant	  mutations	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that	  are	  present	  in	  genes	  coding	  for	  proteins,	  which	  play	  a	  crucial	  role	  in	  the	  repair	  mechanism	  of	  DNA,	   i.e.	  HR.	  Such	  mutations	  may	   lead	   to	   loss	  of	   function	  and	  hence	  faulty	   repair.	  Moreover,	  nonfunctional	  HR	  predisposes	  not	  only	   to	   cancer,	  but	  also	  can	  lead	  to	  infertility,	  birth	  defects,	  and	  negatively	  affects	  development.65	  	  
1.4.2 Defects	   in	   recombination	   genes	   lead	   to	   cancers,	   Fanconi	   anemia	   and	  
developmental	  problems	  	  	  	   Monoallelic	   mutations	   in	   PALB2,	   BRCA1,	   and	   BRCA2	   are	   linked	   to	   hereditary	  breast	   and	   ovarian	   cancers.87,88	   Similar	   outcome	   can	   be	   observed	   for	   RAD51	  paralogs,	  where	  mutations	   in	  RAD51B,	  RAD51C,	   XRCC2,	   and	  XRCC3	   lead	   to	   breast	  and	  ovarian	  cancers	  as	  well.26,89	  Moreover,	  mutation	  of	  PALB2	  in	  one	  allele	  can	  also	  lead	   to	   a	   higher	   risk	   of	   development	   of	   pancreatic	   cancer.26,90,89,91	   Interestingly,	  women	   with	   mutations	   in	   PALB2	   are	   predisposed	   eight	   to	   nine	   more	   times	   to	  develop	   cancer	   in	   comparison	   to	   unaffected	   population	   aged	   below	   40	   years.91	  Moreover,	   mutations	   in	   both	   alleles	   of	   PALB2,	   RAD51C,	   BRCA1,	   and	   BRCA2	  subsequently	   lead	   to	   Fanconi	   anemia,	   a	   rare	   childhood	   disease,	   which	   manifests	  various	  defects	  in	  development	  including	  bone	  marrow	  failure	  as	  well	  as	  increased	  susceptibility	  of	  the	  affected	  individuals	  to	  cancer.26,92,93	  	   HR	  is	  a	  largely	  accurate	  DNA	  repair	  pathway,	  which	  is	  taking	  place	  mostly	  in	  the	  S-­‐phase.	   The	   recombination	   machinery	   can	   accurately	   copy	   missing	   information	  from	  the	  homologous	  template	  and	  avoid	  unwanted	  introduction	  of	  a	  mutation	  into	  the	  DNA,	  hence	  it	  is	  a	  preferred	  repair	  pathway	  despite	  its	  rather	  slow	  progression.	  However,	   in	   the	   absence	   of	  HR,	  NHEJ	   or	   SSA	   pathways	   compensate	   for	   the	   repair	  defect,	   however	   such	   repair	   mechanisms	   are	   error-­‐prone	   and	   may	   potentially	  introduce	  mutations	  or	  lead	  to	  deletions.	  Such	  scenario	  can	  arise	  especially	  when	  the	  critical	   factors	   in	   the	   repair	   machinery	   fail	   to	   perform	   their	   task.86	   For	   example,	  mutations	  interfering	  with	  BRCA2's	  ability	  to	  interact	  with	  crucial	  factors	  of	  HR	  such	  as	  RAD51	  or	  RPA	  result	   in	  a	   failure	   to	  complete	   the	  repair.	  For	  example,	  mutation	  BRCA2	   Y42C,	   which	   impairs	   RPA	   and	   BRCA2	   interaction,	   predisposes	   affected	  individuals	  to	  cancer.40	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   BRCA2	  contains	  two	  sequence	  motifs	  necessary	  for	  its	  transportation	  between	  the	  cytoplasm	  and	  nucleus.	   These	   are	   nuclear	   export	   sequence/signal	   (NES1;	   a	   region	  located	  between	  the	  amino	  acid	  sequence	  1383-­‐1393)	  94,95	  and	  nuclear	   localization	  sequence	   (NLS),	   which	   is	   located	   in	   the	   C-­‐terminus	   of	   BRCA2.95	   NLS	   and	   NES	   are	  responsible	   for	   shuttling	   of	   BRCA2	   from	   cytoplasm	   to	   nucleus	   across	   the	   nuclear	  envelope	  and	  vice	  versa.94	  Upon	  DNA	  damage,	  DSS1	  masks	  NES,	  so	  that	  BRCA2	  can	  be	  transported	  to	   the	  nucleus.	  Similarly,	  once	  DSS1	  masks	  NES,	  BRCA2	  can	  effectively	  transport	   RAD51	   oligomers	   to	   the	   nucleus	   to	   the	   sites	   of	   DNA	   damage.	   In	   accord,	  BRCA2D2723H	  point	  mutation	  that	  impairs	  DSS1	  binding	  to	  BRCA2	  results	  in	  a	  failure	  to	  effectively	  transport	  RAD51	  to	  the	  sites	  of	  damage	  95	  and	  is	  commonly	  associated	  with	  breast	  and	  ovarian	  cancer.96	  	   Missing	   function	   of	   BRCA2	   can	   also	   result	   in	   developmental	   problems.	   An	  example	   is	   the	   interaction	   between	   BRCA2	   and	   DSS1,	   which	   is	   impaired	   in	   split	  hand/split	  foot	  (SHFM).	  As	  the	  name	  suggests,	  mutations	  in	  the	  DSS1	  were	  originally	  identified	   in	   individuals	   affected	   by	   malformations	   of	   the	   limbs,	   hands	   and	   feet,	  resulting	  in	  a	  so	  called	  "lobster	  claw	  deformity"	  97.	  DSS1,	  an	  evolutionary	  conserved	  protein,	   binds	   the	   BRCA2	   at	   amino	   acid	   residues	   2472-­‐2957.97	   	   Lack	   of	   such	  interaction	  leads	  to	  failure	  to	  complete	  the	  HR.	  Indeed,	  depletion	  of	  DSS1	  resembles	  the	  phenotype	   of	  BRCA2-­‐depleted	   cells,	   specifically	   in	   the	   hypersensitivity	   to	  DNA	  damaging	   agents.	   The	   importance	   of	   DSS1-­‐BRCA2	   interaction	   lies	   in	   the	   fact	   that	  DSS1	  is	  crucial	  for	  delivery	  of	  BRCA2	  (and	  RAD51)	  to	  the	  nucleus.95	  	  
1.4.3 Towards	  targeted	  therapy:	  exploiting	  synthetic	  lethal	  interactions	  	  	   Knowing	   the	   exact	   molecular	   mechanism,	   which	   leads	   to	   the	   risk	   and/or	  development	   of	   cancer,	   is	   crucial	   in	   order	   to	   design	   appropriate	   cancer	   therapy,	  which	   can	   be	   targeted	   to	   the	   patient	   depending	   on	   the	   genetic	   footprint	   of	   the	  disease.	  Synthetic	  lethality	  is	  a	  phenomenon	  when	  two	  parallel	  pathways	  can	  lead	  to	  a	   similar	   biological	   outcome.	   Disabling	   one	   pathway	   does	   not	   have	   a	   great	   effect,	  however	  when	   both	   pathways	   are	   inactive,	   it	   results	   in	   a	   synthetic	   lethality.98	   An	  example	   for	   the	   exploitation	   of	   synthetic	   lethality	   is	   the	   treatment	   of	   BRCA2-­‐deficient	   tumors	   with	   PARP	   inhibitors,	   marketed	   under	   the	   label	   Lynparza	  (olaparib).99,100,98	  Poly(ADP-­‐ribose)	  polymerase	  (PARP1)	  is	  an	  enzyme	  that	  binds	  to	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the	  sites	  of	  DNA	  damage.	  BRCA2-­‐deficient	  cells/tumors	  were	  shown	  to	  be	  sensitive	  to	  PARP	  inhibitors,	  therefore	  this	  drug	  is	  used	  for	  killing	  the	  BRCA2-­‐deficient	  tumors	  in	  triple	  negative	  breast/ovarian	  cancer	  patients.100	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2 RESULTS	  	  
2.1 Summary	  of	  results	  	  
2.2 Preliminary	  results	  	  
2.2.1 DNA	  binding	  activity	  of	  MMS22L-­‐TONSL	  and	  MMS22L	  alone	  	  	  	   To	  determine	  whether	  MMS22L-­‐TONSL	  binds	  DNA,	  we	  performed	  electrophoretic	  mobility	   shift	   assay	   (EMSA)	   with	   various	   radiolabelled	   DNA	  molecules.	  We	   found	  that	  MMS22L-­‐TONSL	  did	  not	  bind	   to	  short	  oligonucleotides	  of	  50	  nt	   in	   length.	  The	  only	  exception	  was	  a	  4-­‐way	  junction,	  where	  low	  DNA	  binding	  was	  detected	  (Figure	  5A).	   Instead,	  MMS22L-­‐TONSL	   bound	   to	   longer	   DNA	   substrates	   (93	   nt),	   albeit	   still	  with	   a	   low	   affinity.	   In	   general,	  we	   did	   not	   observe	  major	   differences	   between	   the	  various	   structures	   tested,	   although	   moderate	   preference	   for	   ssDNA	   (93	   nt)	   and	  branched	   structures,	   such	   as	   4-­‐way	   junctions	   and	   replication	   fork	   substrates,	  was	  observed	   (Figure	   5B).	   Nevertheless,	   the	   difference	   between	   the	   most	   and	   least	  preferred	   substrates	  was	   2-­‐3	   fold.	   The	   relatively	   low	   concentration	   of	   our	   protein	  preparations	  did	  not	  allow	  us	  to	  establish	  Kd	  values.	  Still,	  based	  on	  the	  trend	  line	  we	  estimate	  DNA	  dissociation	  constants	  at	  approx.	  50-­‐120	  nM	  range.	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Figure	  5:	  A-­‐	  Binding	  of	  MMS22L-­‐TONSL	  complex	  to	  50nt	  long	  substrates.	  B-­‐	  Binding	  of	   MMS22L-­‐TONSL	   complex	   to	   93	   nt/bp	   substrates	   where	   4WJ	   stands	   for	   '4-­‐way	  junction'.	  	  	  	  	  	   Next	  we	  tested	  MMS22L-­‐TONSL	  binding	  to	  bacteriophage	  M13-­‐based,	  7250	  nt/bp	  long	  DNA	  substrates.	   In	  contrast	   to	   the	  oligonucleotide-­‐based	  structures,	  MMS22L-­‐TONSL	   bound	   long	   DNA	   with	   a	   high	   affinity	   (Figure	   6A).	   This	   suggested	   that	   the	  heterodimer	  oligomerizes	  upon	  DNA	  binding,	  and	  DNA-­‐bound	  multimers	  bind	  DNA	  more	   strongly	   then	  monomers	   or	   small	   oligomers.	   	  We	   also	   tested	   the	   binding	   of	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MMS22L	   protein	   alone,	   which	   showed	   dramatically	   lower	   DNA	   binding	   than	   the	  heterodimer.	   Thus,	   both	   subunits	   are	   required	   for	   stable	   DNA	   binding	   (Figure	   6B	  and	  C).	  	  	  	  
	  	  
Figure	  6:	  	  A,	  C-­‐	  MMS22L-­‐TONSL	  binds	  long	  stretches	  of	  ssDNA	  and	  dsDNA	  with	  high	  affinity.	  B,	  C-­‐	  MMS22L	  alone	  does	  not	  bind	  long	  stretches	  of	  ssDNA	  and	  dsDNA.	  hRPA	  is	  a	  positive	  control.	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2.2.2 The	   MMS22L-­‐TONSL	   heterodimer	   directly	   promotes	   RAD51-­‐dependent	  
recombination	  upon	  replication	  stress	  	  	  	  Wojciech	  Piwko,	  Lucie	   J.	  Mlejnkova,	  Karun	  Mutreja,	  Alexander	  Smirnov,	  Mia	  M.	  L.	  Brodersen,	   Diana	   Stafa,	   Ralph	   Zellweger,	   Andreas	   Sturzenegger,	   Pavel	   Janscak,	  Massimo	  Lopes,	  Matthias	  Peter,	  and	  Petr	  Cejka.	  	  
Manuscript.	  	  I	  designed	   the	  biochemistry	  part	  of	   the	   research	   together	  with	  P.C.	  and	  performed	  the	  experiments.	  I	  analyzed	  the	  biochemistry	  data	  together	  with	  P.C.	  and	  wrote	  the	  manuscript	  together	  with	  P.C.	  and	  W.P.	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2.2.3 Additional	  results	  
2.2.3.1 MBP-­‐tagged	  RAD51	  purification	  	  
Successful	  purification	  of	  MBP-­‐tagged	  RAD51	  from	  bacteria	  	  	  Introduction:	  Previous	  RAD51	  purification	  with	  intein-­‐tagged	  RAD51,	  as	  described	  in	  the	  manuscript	  (section	  2.2.2),	  resulted	  in	  a	  relatively	  low	  concentration	  of	  a	  final	  protein	  prep	  (~6.7	  -­‐	  13.5	  µM).	  However,	  subsequent	  experiment	  stated	  in	  section	  2.2.3.3,	  required	  higher	  concentration	  of	  RAD51.	  Therefore	  we	  set	  out	  to	  design	  new	  construct	  with	  MBP-­‐tagged	  RAD51	  as	  MBP	  tag	  binds	  amylose	  resin	  with	  higher	  affinity	  than	  intein	  to	  chitin	  beads.	  	  Results	  and	  Discussion:	  We	  successfully	  purified	  two	  different	  preps	  of	  RAD51,	  which	  concentrations	  were	  24	  µM	  and	  72	  µM	  (Figure	  1	  in	  this	  chapter,	  page	  93).	  	  
2.2.3.2 In	  vitro	  binding	  assay	  with	  mitochondrial	  SSB	  as	  a	  control	  	  
MMS22L-­‐TONSL	  specifically	  binds	  RPA-­‐coated	  ssDNA	  	  	  Introduction:	  In	  the	  previous	  section	  we	  showed	  that	  MMS22L-­‐TONSL	  binds	  RPA-­‐coated	  ssDNA.	  However,	  it	  was	  not	  entirely	  clear,	  whether	  such	  interaction	  is	  specific.	  To	  test	  the	  specificity	  of	  the	  MMS22L-­‐TONSL-­‐RPA	  interaction,	  the	  mitochondrial	  single-­‐strand	  binding	  protein	  (mtSSB)	  was	  pre-­‐bound	  to	  biotinylated	  oligonucleotide	  and	  MMS22L-­‐TONSL	  was	  added	  and	  compared	  RPA-­‐coated	  ssDNA.	  	  Results	  and	  Discussion:	  As	  expected,	  MMS22L-­‐TONSL	  bound	  to	  RPA-­‐coated	  ssDNA	  but	  did	  not	  bind	  to	  mtSSB-­‐coated	  ssDNA.	  This	  result	  clearly	  shows	  that	  MMS22L-­‐TONSL-­‐RPA	  interaction	  is	  specific	  (Figure	  2	  in	  this	  chapter,	  page	  94).	  	  	  	  	  	  	  	  
	   88	  
2.2.3.3 Ternary	  complex	  	  	  
MMS22L-­‐TONSL	  and	  RAD51	  bind	  to	  RPA-­‐coated	  ssDNA	  	  	  Introduction:	  MMS22L-­‐TONSL	  binds	  to	  RPA-­‐coated	  ssDNA.	  Since	  MMS22L-­‐TONSL	  is	  potentially	  a	  recombination	  mediator,	  the	  key	  question	  was	  to	  ask	  whether	  MMS22L-­‐TONSL	  unloads	  RPA	  and	  helps	  to	  load	  RAD51	  onto	  ssDNA	  filament.	  The	  other	  scenario	  would	  be,	  that	  MMS22L-­‐TONSL	  brings	  RAD51	  to	  RPA-­‐coated	  ssDNA	  by	  forming	  a	  ternary	  complex.	  	  Results	  and	  Discussion:	  We	  showed	  that	  MMS22L-­‐TONSL	  probably	  does	  not	  load	  RAD51	  onto	  RPA-­‐coated	  ssDNA,	  as	  the	  levels	  of	  detected	  RPA	  were	  unaffected	  upon	  addition	  of	  MMS22L-­‐TONSL	  and	  RAD51	  (Figure	  3,	  lane3,	  page	  95).	  Nevertheless,	  we	  showed	  that	  MMS22L-­‐TONSL	  binds	  RAD51-­‐coated	  ssDNA.	  Furthermore,	  we	  also	  detected	  MMS22L-­‐TONSL,	  RPA1/2,	  and	  RAD51	  in	  the	  pull-­‐downs.	  However,	  it	  is	  not	  clear,	  whether	  RAD51	  was	  bound	  to	  RPA-­‐coated	  ssDNA	  via	  MMS22L-­‐TONSL,	  therefore	  this	  is	  yet	  to	  be	  determined.	  	  	  	  
2.2.3.4 Mapping	  of	  MMS22L-­‐RAD51	  and	  -­‐RPA	  interacting	  sites/regions	  	  
Successful	  purification	  of	  various	  MMS22L	  fragments	  from	  Sf9	  insect	  cell	  system	  	  	  Introduction:	  So	  far,	  only	  TONSL	  subunit	  domain	  structure	  has	  been	  described	  as	  discussed	  above.	  However,	  no	  information	  is	  provided	  on	  structure	  of	  MMS22L.	  In	  the	  previous	  section,	  we	  showed	  that	  MMS22L	  subunit	  alone	  has	  the	  capacity	  to	  bind	  RPA-­‐coated	  ssDNA	  (S2J,	  page	  82)	  and	  also	  directly	  binds	  RAD51	  (ref	  to	  figure).	  We	  therefore	  wanted	  to	  analyse	  interaction	  sites/regions	  of	  MMS22L-­‐RPA	  and	  MMS22L-­‐RAD51.	  To	  do	  so,	  we	  designed	  20	  MMS22L	  fragments	  mapping	  the	  entire	  MMS22L	  (see	  Figure	  4A	  in	  this	  section	  and	  supplementary	  information	  in	  chapter	  5.2),	  which	  were	  cloned	  into	  pFastBac	  vector.	  Since	  these	  fragments	  were	  very	  long,	  we	  opted	  to	  use	  Sf9	  insect	  cell	  system	  for	  expression.	  	  	  
	   89	  
Results	  and	  Discussion:	  We	  successfully	  purified	  all	  fragments.	  Next,	  we	  plan	  to	  test	  them	  in	  pull-­‐down	  assays	  to	  identify	  interaction	  sites	  with	  RPA	  and	  RAD51.	  	  	  	  	  	  	  
Experimental	  procedures	  	  	  
Electromobility	  shift	  assay	  
	  The	  binding	  reactions	  were	  performed	  as	  described	  previously.	  101	  The	  binding	  buffer	  was	  composed	  of	  25	  mM	  Tris-­‐HCl	  (pH	  7.5),	  2	  mM	  Mg(OAc)2,	  1	  mM	  dithiothreitol,	  and	  0.1	  mg/ml	  bovine	  serum	  albumin	  (New	  England	  BioLabs).	  The	  oligonucleotides	  were	  used	  as	  listed	  in	  the	  supplementary	  information	  5.1.	  ssDNA	  
(50	  nt)	  was	  generated	  by	  32P	  radiolabeling	  5'	  end	  of	  X12-­‐3.	  	  dsDNA	  (50	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  and	  X12-­‐4	  C	  in	  1:2	  molar	  ratio.	  5'	  tailed	  substrate	  (50	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  and	  X12-­‐4	  SC	  in	  1:2	  molar	  ratio.	  3'	  tailed	  substrate	  (50	  nt)	  was	  generated	  by	  annealing	  radiolabeled	  5'	  end	  of	  X12-­‐3	  SC	  and	  X12-­‐4	  NC	  in	  1:2	  molar	  ratio.	  4-­‐way	  junction	  (50	  nt)	  was	  generated	  by	  annealing	  radiolabeled	  5'	  end	  of	  PC	  1253	  and	  PC	  1254,	  PC	  1255,	  PC	  1256	  in	  1:2:2:2	  molar	  ratio.	  ssDNA	  (93	  nt)	  was	  generated	  by	  32P	  radiolabeling	  5'	  end	  of	  X12-­‐3	  TOP	  L.	  dsDNA	  (93	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  BOTTOM	  	  LC	  in	  1:2	  molar	  ratio.	  2-­‐way	  substrate	  (93	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  HJ3	  in	  1:2	  molar	  ratio.	  Replication	  fork	  (RF)	  
substrate	  (93	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  HJ	  1S,	  X12-­‐3	  HJ	  2Sb,	  and	  X12-­‐3	  HJ3	  in	  1:2:2:2	  molar	  ratio.	  4-­‐way	  
junction	  substrate	  (93	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  HJ1,	  X12-­‐3	  HJ2,	  and	  X12-­‐3	  HJ3	  in	  1:2:2:2	  molar	  ratio.	  Nicked	  
4-­‐way	  junction	  (n4W)	  substrate	  (93	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  HJ1,	  X12-­‐3	  HJ2	  Sa,	  X12-­‐3	  HJ	  Sb,	  X12-­‐3	  HJ3	  in	  1:2:2:2:2	  molar	  ratio.	  4WJ-­‐3'	  tailed	  substrate	  (93	  nt)	  was	  generated	  by	  annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  HJ	  1,	  X12-­‐3	  HJ2	  Sb,	  and	  X12-­‐3	  HJ3	  in	  1:2:2:2	  molar	  ratio.	  4WJ-­‐5'	  tailed	  substrate	  (93	  nt)	  was	  generated	  by	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annealing	  32P	  radiolabeled	  5'	  end	  of	  X12-­‐3	  TOP	  L	  and	  X12-­‐3	  HJ	  1S,	  X12-­‐3	  HJ2,	  and	  X12-­‐3	  HJ3	  in	  1:2:2:2	  molar	  ratio.	  	  	  	  	  	  
Preparation	  of	  recombinant	  MBP-­‐RAD51	  protein	  
	  	  	  RAD51	  was	  expressed	  from	  a	  pMALT-­‐p	  vector	  where	  it	  was	  fused	  to	  an	  MBP-­‐tag	  at	  its	  N-­‐terminus.	  This	  vector	  was	  generated	  as	  follows.	  RAD51	  was	  amplified	  from	  pTXB3	  vector	  by	  using	  forward	  primer:	  	  F-­‐R51:	  5'CTACTAGGATCCATGGCAATGCAGATGCAGCTT-­‐3'	  and	  reverse	  primer:	  R-­‐R51:	  5'-­‐	  CTTCTTCTGCAGTCAGTCTTTGGCATCTCCCACTCC-­‐3'.	  PCR	  product	  was	  digested	  with	  BamHI	  and	  PstI	  and	  cloned	  into	  pMALT-­‐p	  vector.	  The	  protein	  was	  expressed	  in	  E.	  
coli	  BL21(DE3)pLysS	  cells	  (Promega)	  and	  purified	  on	  amylose	  resin	  (New	  England	  Biolabs)	  according	  to	  manufacturer's	  recommendation.	  Briefly,	  the	  pellets	  were	  lysed	  with	  lysis	  buffer	  [50	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  phenylmethanesulfonyl	  fluoride	  (PMSF),	  1	  mM	  dithithreitol,	  10%	  glycerol,	  500	  mM	  NaCl,	  and	  protease	  inhibitors	  (1;500;	  Sigma)].	  Then,	  the	  lysate	  was	  sonicated	  six	  times	  at	  70%	  intensity	  and	  loaded	  onto	  column	  with	  pre-­‐equlibrated	  amylose	  resin.	  The	  immobilized	  sample	  was	  further	  washed	  with	  wash	  buffer	  I	  [50	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  dithithreitol,	  10%	  glycerol,	  1	  M	  NaCl]	  and	  wash	  buffer	  II	  [50	  mM	  Tris-­‐HCl	  pH	  7.5,	  1	  mM	  dithithreitol,	  10%	  glycerol,	  300	  mM	  NaCl].	  MBP-­‐RAD51	  was	  eluted	  with	  elution	  buffer	  [wash	  buffer	  II	  supplemented	  with	  10	  mM	  maltose].	  The	  MBP	  tag	  was	  cleaved	  with	  PreScission	  protease	  for	  2	  h	  at	  4	  °C.	  The	  cleaved	  RAD51	  was	  diluted	  with	  50	  mM	  Tris-­‐HCl	  (pH	  7.5)	  to	  a	  final	  concentration	  of	  150	  mM	  NaCl,	  and	  loaded	  onto	  pre-­‐equilibrated	  HiTrap	  Q	  HP	  column	  (GE	  Healthcare).	  The	  column	  was	  washed	  with	  R	  buffer	  containing	  20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  1	  mM	  EDTA,	  0.5	  mM	  dithiothreitol,	  10%	  glycerol	  supplemented	  with	  150	  mM	  NaCl.	  RAD51	  was	  eluted	  with	  10	  ml	  gradient	  of	  150	  mM	  to	  700	  mM	  NaCl	  in	  R	  buffer	  supplemented	  with	  1M	  NaCl.	  Next	  day,	  the	  final	  sample	  was	  mixed	  with	  PreScission	  protease	  to	  cleave	  the	  uncleaved	  MBP	  tag	  and	  dialyzed	  for	  2.5	  h	  against	  dialysis	  buffer	  containing	  20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  20%	  glycerol,	  100	  mM	  NaCl,	  1	  mM	  dithiothreitol.	  The	  residual	  cleaved	  MBP	  tag	  was	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captured	  on	  amylose	  resin	  during	  1	  h	  batch-­‐wise	  incubation.	  The	  final	  sample	  was	  then	  aliquoted	  and	  stored	  at	  -­‐80	  °C.	  	  	  	  	  	  
In	  vitro	  binding	  assay	  with	  mtSSB	  




Ternary	  complex	  assay	  
	  The	  assay	  was	  performed	  similarly	  as	  described	  previously	  with	  several	  changes.	  20	  Briefly,	  RPA	  (100	  nM),	  MMS22L-­‐TONSL	  (50	  nM)	  and	  RAD51	  (500	  nM)	  were	  pre-­‐incubated	  at	  37	  ºC	  for	  10	  min	  according	  to	  a	  reaction	  scheme	  shown	  in	  the	  Figure	  3	  (chapter	  2.2.3)	  in	  binding	  buffer	  supplemented	  with	  ATP	  (20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  120	  mM	  NaCl,	  0.1%(v/v)	  Triton	  X-­‐100,	  2	  mM	  CaCl2,	  10	  mM	  Mg(OAc)2,	  2	  mM	  ATP,	  1	  mM	  dithiothreitol,	  and	  0.1	  mg/ml	  bovine	  serum	  albumin)	  or	  without	  ATP	  (20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  120	  mM	  NaCl,	  0.1%(v/v)	  Triton	  X-­‐100,	  2	  mM	  CaCl2,	  10	  mM	  Mg(OAc)2,	  1	  mM	  dithiothreitol,	  and	  0.1	  mg/ml	  bovine	  serum	  albumin)	  together	  with	  biotinylated	  B-­‐90-­‐mer.	  Reactions	  were	  incubated	  with	  pre-­‐equilibrated	  Dynabeads®	  M-­‐280	  Streptavidin	  (Invitrogen)	  rotating	  at	  4	  ºC	  for	  30	  min.	  Then	  the	  beads	  were	  washed	  four	  times	  with	  wash	  buffer	  with	  or	  without	  2	  mM	  ATP	  [20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  120	  mM	  NaCl,	  0.1%(v/v)	  Triton	  X-­‐100,	  2	  mM	  CaCl2,	  10	  mM	  Mg(OAc)2,	  1	  mM	  dithiothreitol].	  The	  protein	  was	  eluted	  by	  boiling	  with	  1x	  protein	  loading	  buffer	  (50	  mM	  Tris,	  pH	  6.8;	  10%	  glycerol;	  1.6%	  sodiumdodecylsulphate,	  0.1	  M	  dithiothreitol;	  0.02%	  bromphenol	  blue)	  and	  1	  µl	  bovine	  serum	  albumin	  at	  95	  ºC	  for	  3	  min	  and	  loaded	  onto	  10	  %	  SDS-­‐polyacrylamide	  gel.	  The	  amounts	  of	  RAD51,	  RPA,	  and	  MMS22L-­‐TONSL	  proteins	  bound	  to	  biotinylated	  DNA	  oligonucleotide	  were	  estimated	  by	  western	  blotting	  using	  a	  polyclonal	  RAD51	  antibody	  specific	  to	  human	  RAD51,	  102	  RPA	  antibody	  (Calbiochem),	  and	  his	  tag	  antibody	  	  (GenScript).	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Mapping	  of	  MMS22L-­‐RAD51	  and	  -­‐RPA	  interacting	  regions	  




Fig.	  1.	  Purified	  RAD51.	  
	  
Fig.	  2.	  MMS22L-­‐TONSL	  does	  not	  bind	  mtSSB-­‐coated	  ssDNA.	  
	  
Fig.	  3.	  MMS22L-­‐TONSL	  binds	  RAD51	  coated	  ssDNA	  in	  the	  presence	  of	  ATP.	  
	  
Fig.	  4.	  Purified	  MMS22L	  fragments	  from	  Sf9	  insect	  cell	  system.	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2.2.4 H4	  K20me0	  marks	  post-­‐replicative	  chromatin	  and	  recruits	  the	  TONSL-­‐MMS22L	  
DNA	  repair	  complex	  	  	  Giulia	  Saredi,	  Hongda	  Huang,	  Colin	  M.	  Hammond,	  Constance	  Alabert,	  Simon	  Bekker-­‐Jensen,	  Ignasi	  Forne,	  Nazaret	  Reverón-­‐Gómez,	  Benjamin	  M.	  Foster,	  Lucie	  
Mlejnkova,	  Till	  Bartke,	  Petr	  Cejka,	  Niels	  Mailand,	  Axel	  Imhof,	  Dinshaw	  J.	  Patel,	  and	  Anja	  Groth.	  	  
In	  print.	  Nature,	  June	  2016.	  	  	  I	  designed	  the	  MMS22L-­‐TONSL	  protein	  purification	  protocol	  together	  with	  P.C.	  and	  purified	  the	  protein	  complex,	  which	  was	  then	  used	  in	  the	  pull-­‐down	  of	  recombinant	  TONSL-­‐MMS22L	  with	  biotinylated	  recombinant	  mononucleosomes	  shown	  in	  the	  main	  Figure	  2d	  (page	  99).	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3 CONCLUSION	  AND	  DISCUSSION	  	  	  The	   key	   step	   in	   HR	   is	   the	   exchange	   of	   RPA	   assembled	   on	   ssDNA	   for	   the	   RAD51	  recombinase,	  which	  forms	  a	  nucleoprotein	  filament	  that	  is	  required	  for	  synapsis	  and	  invasion	   into	   homologous	   DNA.4,1	   However,	   RPA-­‐coated	   ssDNA	   possesses	   an	  inhibitory	   effect	   on	   RAD51	   nucleoprotein	   filament	   formation.	   Recombination	  mediators,	   such	   as	   BRCA2	   and	   RAD51	   paralogs,	   including	   RAD51B,	   RAD51C,	  RAD51D,	  XRCC2,	  and	  XRCC3	  are	  known	  to	  regulate	  this	  step	  of	  HR.	  20,34,105	  However,	  the	  exact	  mechanism	  and	  interplay	  in	  between	  RAD51,	  BRCA2	  and	  RAD51	  paralogs	  is	  not	  entirely	  clear.	  Recent	   studies	   conducted	   by	   four	   independent	   groups	   71-­‐74,	   identified	   a	   new	  potential	   recombination	  mediator,	  MMS22L-­‐TONSL.	  MMS22L-­‐TONSL	  colocalized	  at	  sites	  of	  DNA	  damage	  upon	  laser	  microirradiation.71,72	  Depletion	  of	  MMS22L-­‐TONSL	  did	  not	  affect	   resection	  after	  DNA	  damage.	   In	  contrast,	  CPT	   treatment	  of	  MMS22L-­‐depleted	   cells	   led	   to	   decrease	   of	   RAD51	   foci	   formation,	   showing	   the	   necessity	   of	  MMS22L-­‐TONSL	   in	  RAD51	   loading	  upon	  DNA	  damage.72	  Hence,	  MMS22L-­‐TONSL	   is	  thought	   to	   be	   another	   recombination	   mediator	   acting	   alongside	   BRCA2	   and/or	  RAD51	   paralogs.	   However,	   whether	   this	   is	   true	   and	   how	   does	   the	   heterodimer	  function	  on	  a	  mechanistic	  level	  is	  not	  clear.	  	  	  Our	  data	  brought	  the	  following	  conclusions:	  
1)	  MMS22L-­‐TONSL	  binds	  long	  stretches	  of	  DNA,	  especially	  to	  RPA-­‐coated	  ssDNA	  -­‐	  Mass	  spectrometry	   analyses	   revealed	   that	  MMS22L-­‐TONSL	   binds	  RPA.71,72	   Furthermore,	  MMS22L-­‐TONSL	  colocalized	  with	  RPA	  foci	  at	  sites	  of	  DNA	  damage.	  71,72	  Therefore	  it	  was	   intriguing,	   whether	   MMS22L-­‐TONSL	   binds	   RPA	   and/or	   RPA-­‐coated	   ssDNA	  directly.	  We	   showed	   that	  MMS22L-­‐TONSL	  binds	  RPA	  directly	   in	   solution,	  however	  the	  interaction	  was	  very	  weak	  (Figure	  S2C	  and	  D,	  page	  82).	  Interestingly,	  once	  RPA	  is	  pre-­‐bound	  to	  ssDNA,	  both	  MMS22L-­‐TONSL	  and	  MMS22L	  bind	  RPA-­‐coated	  ssDNA	  filament	   with	   strong	   affinity	   (Figure	   2C,	   page	   75	   and	   Figure	   S2J,	   page	   82).	   This	  suggested	   that	  RPA	  may	   serve	  as	   a	   recruiting	  platform	   for	  MMS22L-­‐TONSL,	  which	  may	   serve	   to	   bring	   the	   heterodimer	   to	   sites	   of	   stalled	   replication	   forks	   or	   ssDNA	  gaps	  behind	  the	  forks.	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2)	  MMS22L-­‐TONSL	  directly	  binds	  RAD51	  and	  RAD51-­‐coated	  ssDNA	  -­‐	  It	  was	  shown	  that	  MMS22L	   or	   TONSL	   depletion	   affects	   RAD51	   foci	   formation	   upon	   treatment	   with	  CPT.71,72	  However	   the	  underlying	  mechanism	  was	  not	  clear.	  Specifically,	   it	  was	  not	  clear	   if	   MMS22L-­‐TONSL	   interacts	   with	   RAD51.	   Here,	   we	   showed	   that	   MMS22L-­‐TONSL	  and	  MMS22L	  alone	  bind	  RAD51	  directly	  (5F	  and	  G,	  page	  78;	  S5K,	  page	  85).	  Furthermore,	  our	  additional	  data	  provide	  evidence	  that	  MMS22L-­‐TONSL	  also	  binds	  RAD51-­‐coated	   ssDNA	   filament	   (see	   section	  2.2.3,	   Figure	  3,	  page	  95).	  This	   suggests	  that	   the	   effect	   of	   MMS22L-­‐TONSL	  might	   be	   rather	   direct	   and	  may	   depend	   on	   the	  physical	  interaction	  between	  MMS22L-­‐TONSL	  and	  RAD51.	  	  
3)	   MMS22L-­‐TONSL	   lowers	   RAD51	   binding	   affinity	   to	   dsDNA	   and	   promotes	   RAD51-­‐
dependent	  strand	  exchange	  activity	   -­‐	  Downregulation	  of	  MMS22L	  and	  TONSL	   led	   to	  approximately	  60%	  reduction	  in	  GFP-­‐positive	  cells	  in	  DR-­‐GFP	  reporter	  assays.72	  This	  suggested	   that	   MMS22L-­‐TONSL	   plays	   an	   important	   function	   in	   homologous	  recombination.	   Together	   with	   the	   RAD51	   foci	   data,	   this	   further	   supports	   the	  hypothesis	   that	   MMS22L-­‐TONSL	   is	   a	   factor,	   which	   plays	   a	   role	   in	   the	   loading	   of	  RAD51	   onto	   RPA-­‐coated	   ssDNA	   filament.72	   However,	   in	   vivo	   data	   cannot	  substantiate/uncover	   the	   exact	   molecular	   mechanism	   how	   MMS22L-­‐TONSL	  functions.	  Recombination	  mediators	  can	  promote	  RAD51	   loading	   in	  multiple	  ways,	  for	  example	  -­‐	  (i)	  by	  overcoming	  inhibitory	  effect	  of	  RPA,	  (ii)	  stabilizing	  the	  RAD51-­‐ssDNA	   nucleoprotein	   filament,	   and	   (iii)	   by	   inhibiting	   RAD51's	   binding	   affinity	   to	  dsDNA,	  which	  is	  inhibitory	  for	  the	  strand	  exchange	  reaction.20,34,54	  Here	  we	  showed	  that	  MMS22L-­‐TONSL	  lowers	  the	  binding	  affinity	  of	  RAD51	  to	  dsDNA	  (Figures	  5C,	  D,	  H,	  K	  on	  page	  78;	  S5A,	  B,	  C,	  H	  on	  page	  85).	  In	  reactions	  where	  both	  double	  and	  single-­‐stranded	   DNA	   are	   present,	   MMS22L-­‐TONSL	   facilitates	   the	   loading	   of	   RAD51	   on	  ssDNA.	   These	   data	   altogether	   point	   out	   that	   MMS22L-­‐TONSL	   is	   a	   recombination	  mediator	  in	  HR.	  It	  may	  specifically	  act	  at	  stalled	  or	  collapsed	  DNA	  replication	  forks	  to	  inhibits	  RAD51's	  binding	  affinity	   towards	  dsDNA	   	  (Figure	  7A	  and	  B,	  page	  80).	  This	  leads	   to	   the	  stimulation	  of	  DNA	  strand	  exchange	   in	  reconstituted	  assays.	  However,	  MMS22L-­‐TONSL	  cannot	  overcome	  the	  inhibitory	  effect	  of	  RPA	  (Figure	  S5N,	  page	  85),	  therefore	   we	   envision	   that	   it	   acts	   synergistically	   with	   other	   recombination	  mediators.	   The	   exact	   interplay	   and	   possible	   synergistic	   effect/cooperation	   of	  MMS22L-­‐TONSL	  with	  other	  mediators	  such	  as	  RAD51	  paralogs	  is	  not	  yet	  clear,	  and	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will	   represent	  a	   challenge	   for	   future	  research.	  Furthermore,	   the	  effect	  of	  MMS22L-­‐TONSL	  on	  recombination	  specifically	   in	   the	  context	  of	   stalled	  replication	   forks	  will	  need	  to	  be	  established.	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5 SUPPLEMENTARY	  INFORMATION	  	  	  
5.1 List	  of	  nucleotides	  	  	  	  
Oligonu
cleotide	  
Sequence	  (5'	  to	  3')	  
X12-­‐3	   GACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATCGC	  
X12-­‐4	  C	   GCGATAGTCTCTAGACAGCATGTCCTAGCAATGTAATCGTCTATGACGTC	  





























PC	  1253	   TGGGTCAACGTGGGCAAAGATGTCCTAGCAATGTAATCGTCTATGACGTT	  
PC	  1254	   TGCCGAATTCTACCAGTGCCAGTGATGGACATCTTTGCCCACGTTGACCC	  
PC	  1255	   GTCGGATCCTCTAGACAGCTCCATGATCACTGGCACTGGTAGAATTCGGC	  
PC	  1256	   CAACGTCATAGACGATTACATTGCTACATGGAGCTGTCTAGAGGATCCGA	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5.2 List	  of	  primers	  and	  sequences	  of	  MMS22L	  fragments	  	  
Primers	  design:	  	  
Forward:	  5'-­‐CTACTA-­‐	  GGGCC''C	  -­‐	  insert	  20nt	  -­‐	  3'	  	  	  (ApaI)	  
Reverse:	  5'-­‐CTTCTT-­‐	  C''TCGAG	  -­‐TTA+	  FLAG+	  insert	  20nt	  (reverse	  complementary)	  -­‐	  3'	  (XhoI)	  	  FLAG	  tag	  sequence	  (AspTyrLysAspAspAspAspLys):	  	  5'-­‐gattacaaggatgacgacgataag-­‐3'	  	  FLAG	  tag	  (reverse	  complementary):	  5'	  -­‐	  CTTATCGTCGTCATCCTTGTAATC	  -­‐3'	  	  	  	  
List	  of	  designed	  primers	  and	  MMS22L	  fragments	  sequences:	  	  1)	  Full	  length	  MMS22L	  (FL)	  
	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACA
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TTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	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2)	  N-­‐100	  (N1)	  
	  
	  	  SF-­‐N1:	  5'-­‐CTACTA	  GGGCCC	  TACAACTTGGAAACCTTGTT	  -­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  TACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTA
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TCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	  	  	  3)	  N-­‐200	  (N2)	  
	  
	  	  SF-­‐N2:	  5'-­‐CTACTA	  GGGCCC	  ATTAAGCTTTTTCCACCGTC-­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  ATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGC
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AGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	  	  	  4)	  N-­‐300	  (N3)	  	   	  	  SF-­‐N3:	  5'-­‐CTACTA	  GGGCCC	  ATTCATCTTCTAGACCACAG-­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	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ATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	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5)	  N-­‐400	  (N4)	  
	   	  	  SF-­‐N4:	  5'-­‐CTACTA	  GGGCCC	  CAATTACGAATGTATCTTCA-­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  	  CAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGT
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GTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	  	  	  6)	  N-­‐500	  (N5)	  
	   	  	  SF-­‐N5:	  5'-­‐CTACTA	  GGGCCCCCTCATCCTTGGAAACAAGT-­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  	  CCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTC
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TTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	   	  	  7)	  C-­‐100	  (C1)	  	   	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐C1:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  TTCTTCTGACCCCACTTGGC	  -­‐3'	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAA
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GCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAA	  	  	  	  8)	  C-­‐200	  (C2)	  
	   	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐P1050:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  CAAAACAGGATGTTGTCCAA	  -­‐3'	  	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTG
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TACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTG	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  9)	  C-­‐300	  (C3)	  	   	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐C3:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  CACAAGAATTCCCATCATTC-­‐3'	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCAT
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CAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTG	  	  	  	  	  10)	  C-­‐400	  (C4)	  
	   	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐C4:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  CATGTACTCTTTTTCAACTG	  -­‐3'	  	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGT
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AGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATG	  	  	  	  11)	  C-­‐500	  (C5)	  
	   	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐P750:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  TGCTAGCAAAGTAAAGTCTG	  -­‐3'	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCC
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TGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCA	  	  	  	  12)	  Full	  length	  MMS22L:	  F1034A	  (FL-­‐FA	  only)	  	  	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  -­‐3'	  	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  
Site	  mutagenesis	  primers:	  Forward:	  F-­‐M22-­‐FA	  5'	  -­‐	  TTGAGCAGTATATTGGGCGAGCTCTTCCAGCTTCACCATATGT	  -­‐3'	  	  Reverse	  (complementary):	  R-­‐M22-­‐FA	  5'-­‐	  ACATATGGTGAAGCTGGAAGAGCTCGCCCAATATACTGCTCAA	  -­‐	  3'	  	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTAT
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ATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAATGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGAGCTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCT
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GTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	  	   	  	  13)	  S1	  (1-­‐600aa)	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  SR-­‐P600:	  5'-­‐CTTCTT	  	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATCCCGGAAAGCACATGAAAATT	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAACGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGG	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14)	  S2	  (601-­‐1243aa)	  	  SF-­‐P601:	  5'-­‐CTACTA	  GGGCCC	  GAGAAAGCAAAGGAATTCTT	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3	  	  GAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAGCAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	  	  	  15)	  S3	  (1-­‐300aa)	  	  SF-­‐P1:	  5'-­‐CTACTA	  GGGCCC	  ATGGAGAACTGTTCTGCTGC	  SR-­‐P300:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AAGTAGAACCCATAATTCTT	  	  ATGGAGAACTGTTCTGCTGCATCGACGTTCCTGACTGACAGCTTAGAGCTGGAGCTGGGGACGGAATGGTGCAAACCTCCTTACTTTTCTTGTGCTGTTGACAACAGAGGAGGAGGAAAACATTTTTCTGGAGAATCCTACCTCTGCAGCGGAGCCCTTAAGCGATTGATTTTGAATCTTGACCCTTTACCAACTAATTTTGAAGAAGATACCTTGGAAATATTTGGCATTCAGTGGGTTACTGAAACAGCATTAGTGAATTCATCTAGAGAACTCTTTCATTTATTCAGGCAACAACTGTACAACTTGGAAACCTTGTTACAGTCCAGTTGTGATTTTGGGAAGGTATCAACTCTACACTGCAAAGCAGACAATATTAGGCAGCAGTGTGTACTATTTCTCCATTATGTTAAAGTTTTCATCTTCAGGTATCTGAAAGTACAGAATGCTGAGAGTC
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ATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTT	  	  	  	  16)	  S5	  (600-­‐900aa)	  	  SF-­‐P600:	  5'-­‐CTACTA	  GGGCCC	  CGGGAGAAAGCAAAGGAATT	  SR-­‐P900:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  CCCGTAAGTTACACCAACAG	  	  CGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGG	  	  	  	  17)	  S6	  (900-­‐1243aa)	  	  SF-­‐P900:	  5'-­‐CTACTA	  GGGCCC	  GGGAACGTCCAGACACTTTC	  SR-­‐P1243:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  AGTATTATCATTTTCCAGTC	  -­‐3'	  	  GGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTGCTGGCATTGAGAAACACAGCCACTATTCCGCCAATATCATCTCTAAAGAAATGCATTGTGCAAGTCATAAGGAAATCCTACCTTGAGTATAAGGGGTCCTCACCTCCTCCTCGCTTAGCATCCATTCTGGCCTTCATCCTCCAACTCTTCAAGGAAACTAACACAGACATTTATGAAGTTGAACTACTCCTCCCTGGCATTTTAAAATGCTTGGTGTTAGTCAGTGAACCACAAGTTAAAAGGCTGGCCACAGAGAACCTGCAATACATGGTAAAAGCCTGCCAAGTGGGGTCAGAAGAAGAACCTTCCTCCCAGCTGACTTCTGTGTTTAGGCAGTTTATCCAGGATTATGGTATGAGGTACTATTACCAGGTTTACAGCATTTTAGAAACAGTAG
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CAACATTGGACCAGCAGGTTGTCATCCACTTGATTTCTACCCTTACTCAGTCTCTGAAGGATTCAGAGCAGAAATGGGGCCTTGGCAGGAATATAGCACAAAGGGAAGCCTATAGCAAACTTTTGTCTCACCTTGGACAGATGGGACAAGATGAGATGCAGAGACTGGAAAATGATAATACT	  	  	  	  18)	  S7	  (150-­‐450aa)	  	  SF-­‐P150:	  5'-­‐CTACTA	  GGGCCC	  GCTGAGAGTCATGTTCCTGT	  SR-­‐P450:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  ATTAGCAAGGCCTTTAAAAG	  	  GCTGAGAGTCATGTTCCTGTCCATCCTTATGAGGCTTTGGAGGCTCAGCTTCCCTCAGTGTTGATTGATGAGCTTCATGGATTACTCTTGTATATTGGACACCTATCTGAACTTCCCAGTGTTAATATAGGAGCATTTGTAAATCAAAACCAGATTAAGCTTTTTCCACCGTCATGGCATTTATTACATCTCCACTTGGATATACATTGGCTGGTGCTAGAAATTCTTTACATGCTGGGTGAAAAATTGAAACAAGTTGTATATGGTCATCAGTTTATGAATCTGGCAAGTGACAATTTAACCAACATCAGCCTATTTGAAGAACATTGTGAAACTCTCCTTTGTGATTTAATAAGCCTGTCACTCAACAGGTACGACAAGGTTAGGTCTTCTGAATCATTAATGAGTGACCAGTGTCCATGTTTATGCATTAAAGAATTATGGGTTCTACTTATTCATCTTCTAGACCACAGAAGTAAATGGTTTGTCTCGGAATCATTTTGGAACTGGTTGAATAAACTACTTAAAACACTGCTTGAAAAATCAAGTGACCGAAGAAGATCCTCTATGCCTGTAATCCAGTCCAGGGATCCATTAGGTTTTAGTTGGTGGATTATTACTCATGTAGCATCATTTTACAAGTTTGATCGCCATGGAGTACCAGATGAAATGAGAAAAGTGGAATCAAATTGGAACTTTGTAGAAGAACTGCTGAAAAAGTCCATCAGTGTTCAGGGTGTCATTCTAGAAGAACAATTACGAATGTATCTTCACTGTTGTTTGACACTTTGTGATTTCTGGGAGCCAAACATTGCAATTGTTACCATTTTATGGGAATATTATAGTAAGAACCTGAATAGTTCCTTCAGTATTTCTTGGCTTCCTTTTAAAGGCCTTGCTAAT	  	  	  	  19)	  S8	  (450-­‐750aa)	  	  SF-­‐P450:	  5'-­‐CTACTA	  GGGCCC	  AATACCATGAAGTCACCCTT	  SR-­‐P750:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  TGCTAGCAAAGTAAAGTCTG	  	  AATACCATGAAGTCACCCTTGTCTATGCTTGAAATGGTGAAGACTTGCTGTTGCGATAAACAAGATCAGGAACTATATAAATCCAGCAGTAGTTATACTATTTTTCTTTGTATTCTGGCAAAAGTTGTTAAAAAAGCAATGAAGAGCAATGGCCCTCATCCTTGGAAACAAGTCAAAGGAAGAATATATTCAAAATTCCATCAAAAAAGAATGGAAGAACTAACTGAAGTTGGTCTACAGAACTTTTTTAGCCTTTTTCTACTGTTAGCAGCTGTTGCAGAGGTAGAAGATGTTGCAAGTCATGTTTTAGACCTCCTGAATTTCCTCAAGCCTGCTTTTGTAACGTCTCAGAGAGCCCTCATTTGGAAGGGTCACATGGCCTTCCTCTTGATGTATGCCCAGAAAAATCTGGACATTGGTGTTTTGGCTGAGAAATTTTCATGTGCTTTCCGGGAGAAAGCAAAGGAATTCTTGGTGTCTAAGAATGAGGAAATGGTACAGAGACAGACTATCTGGACCCTTCTTTCCATATACATTGATGGTGTTCAAGAAGTGTTTGAGACCAGCTATTGCTTGTATCCTTCCCATGAAAAACTGCTTAATGATGGATTTAGTATGCTTCTGCGAGCATGTCGAGAATCTGAACTTAGGACAGTATTGAGCTTCCTACAAGCTGTTCTGGCCAGAATCAGGAGTATGCATCAACAATTGTGTCAGGAACTTCAAAGGGACAATGTGGACCTATTTGTACAGTCTTCATTATCGGCTAAAGAGCGCCACCTTGCTGCAGTTGCCAGTGCACTGTGGAGACATTTCTTTTCATTTTTGAAGAGTCAGAGAATGTCACAGGTAGTGCCTTTCTCACAACTTGCGGATGCAGCTGCAGACTTTACTTTGCTAGCA	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  20)	  S9	  (750-­‐1050aa)	  	  SF-­‐P750:	  5'-­‐CTACTA	  GGGCCC	  GCAATGGACATGCCAAGCAC	  SR-­‐P1050:	  5'-­‐CTTCTT	  CTCGAG	  TTACTTATCGTCGTCATCCTTGTAATC	  CAAAACAGGATGTTGTCCAA	  	  GCAATGGACATGCCAAGCACAGCTCCATCAGATTTTCAGCCTCAGCCAGTTATATCAATTATTCAACTTTTTGGTTGGGATGATATCATCTGCCCTCAAGTTGTAGCAAGATATTTAAGTCATGTCCTACAAAATAGCACATTATGTGAAGCACTTTCTCATTCAGGCTATGTATCTTTTCAAGCCTTAACCGTAAGATCATGGATTCGTTGTGTTTTGCAAATGTATATTAAAAACCTCTCTGGGCCTGATGATTTGCTCATAGATAAAAATCTGGAAGAGGCAGTTGAAAAAGAGTACATGAAACAGTTGGTCAAACTGACAAGATTACTATTTAATCTCTCAGAAGTAAAGAGTATTTTCTCAAAGGCCCAAGCTGAATATTTATCCATCTCAGAAGACCCTAAAAAAGCACTTGTTCGATTCTTTGAGGCTGTTGGTGTAACTTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAAGTCCTTGGAATACCTTGGTGAAGTATTAAAATATATTAAGCCTTATTTGGGAAAAAAAGTTTTCAGTGCAGGGCTGCAGCTGACTTATGGAATGATGGGAATTCTTGTGAAATCATGGGCACAAATCTTTGCCACTTCTAAAGCCCAAAAATTACTATTCCGGATCATAGATTGTTTACTGCTGCCACATGCAGTATTACAGCAAGAGAAGGAACTGCCTGCACCTATGTTGTCAGCAATTCAGAAAAGTCTTCCTTTGTATCTCCAGGGCATGTGTATCGTGTGTTGTCAATCTCAAAATCCGAATGCCTATTTGAATCAATTGCTAGGGAATGTTATTGAGCAGTATATTGGGCGATTTCTTCCAGCTTCACCATATGTTTCAGATCTTGGACAACATCCTGTTTTG	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